Drug, bio-affecting and body treating compositions inventions 08/08

20080206130 - In vivo panning for ligands to radiation-induced molecules: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080206131 - Compositions and method for multimodal imaging: Provided are signal modifying compositions for medical imaging comprising a carrier and two or more signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect to the signal modifying agents, which enables prolonged contrast imaging without significant depletion of the signal... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080206132 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.a.

20080206133 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.a.

20080206134 - Radio-opaque hemostatic agents and devices and methods for the delivery thereof: A radiographic composition for promoting the formation of clots in blood includes a zeolite and iodine. A device for promoting the clotting of blood at an internal wound site includes a catheter; a delivery instrument insertable through the catheter; a radioopaque blood clotting agent that deliverable through the delivery instrument;... Agent: Michaud-duffy Group LLP

20080206135 - Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty... Agent: Edwards Angell Palmer & Dodge LLP

20080206136 - Binding peptidomimetics and uses of the same: A multimeric peptidomimetic that comprises two or more monomers is disclosed. The monomers comprise an exocyclic peptide comprising a ring structure, a flexible linker sequence and a multimeric motif. Use of the monomers, a nucleic acid molecule encoding monomers, recombinant expression vectors comprising the nucleic acid molecule and host cells... Agent: Pepper Hamilton LLP

20080206137 - 11c-labeled benzyl-lactam compounds and their use as imaging agents: The invention relates to “C-labeled compounds, their preparation, compositions comprising an effective amount of a “C-labeled compound, and the use of a “C-labeled compound as a radiopharmaceutical for positron emission tomography.... Agent: Ge Healthcare, Inc.

20080206138 - Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives: Independent of the position and type of the radioactive label, the compounds according to the invention are potent inhibitors of steroid P450c11 hydroxylation and bind with high affinity on sites of cortisol secretion. In order to avoid saturation of receptor sites, high specific activity labeling is mandatory for application in... Agent: Lerner Greenberg Stemer LLP

20080206140 - Cspcna isoform antibodies and uses thereof: Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed.... Agent: Barnes & Thornburg LLP

20080206139 - Delivery system for diagnostic and therapeutic agents: Nanovesicles are specifically targeted to abnormal cells. The targeting moiety is conjugated to the nanovesicle which comprises a therapeutic composition. These nanovesicles are useful in treatment of a wide spectrum of disorders.... Agent: Akerman Senterfitt

20080206142 - Novel peptides that promote lipid efflux: Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080206141 - Optical imaging contrast agents: The invention relates to optical imaging contrast agents. More specifically the invention relates to optical imaging activatable contrast agent for use in diagnosis and for monitoring the effect of treatment. The contrast agent employs a combined targeting and activation approach and comprises a target binding ligand (V), an enzyme cleavable... Agent: Ge Healthcare, Inc.

20080206143 - Blockade of elr+cxc chemokines as a treatment for inflammatory and autoimmune disease: Experimental autoimmune encephalomyelitis (EAE) is a ThI-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). Herein it is demonstrated that CXCR2, a chemokine receptor involved in the recruitment of neutrophils, is expressed in tissues with EAE lesions. Blockade or... Agent: Fish & Richardson P.c.

20080206144 - Mdr1 variants and methods for their use: This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an... Agent: Klarquist Sparkman, LLP

20080206146 - Functionalized magnetic nanoparticles and methods of use thereof: The present invention provides functionalized magnetic nanoparticles comprising a functional group, which functionalized magnetic nanoparticles exhibit differential binding to a tissue, indulging brain tissue, bone, and vascular tissues. The present invention further provides compositions, including pharmaceutical compostions, comprising a subject functionalized magnetic nanoparticle. The present invention further provides diagnostic and... Agent: Bozicevic, Field & Francis LLP

20080206145 - Gastro-retentive diagnostic assemblies: The present invention provides a gastro-retentive diagnostic assembly (GRDA) for use in determining a condition of a subject's gastrointestinal tract (GI tract), comprising a folded single or multi-layered device comprising a diagnostic utility, such as a contrasting agent, the device prior to folding being essentially planar, and included in a... Agent: Nath & Associates

20080206150 - Nanoparticles for imaging atherosclerotic plaque: Atherosclerosis is an inflammatory disease of the arterial walls and represents a significant health problem in developed nations. Described is a targeted Magnetic Resonance Imaging (MRI) contrast agent for in vivo imaging of early stage atherosclerosis. Early plaque development is characterized by the influx of macrophages, which express a class... Agent: Morrison & Foerster LLP

20080206152 - In vivo expression profiling: The present invention relates to in vivo expression profiling using a plurality of specific targeting moieties each labelled with a different compound which allows to identify simultaneously the binding of each targeting moiety to a target.... Agent: Philips Intellectual Property & Standards

20080206151 - Liposomes: The present invention relates to a process for the manufacture of targeting liposomes comprising vector compounds conjugated to the hydrophilic part of modified phospholipids. The present invention provides the modified phospholipids and liposomes containing said modified phospholipids.... Agent: Ge Healthcare, Inc.

20080206147 - Method for the use of [11c]carbon monoxide in labeling synthesis of 11c-labelled acids by photo-induced free radical carbonylation under mild conditions using sulfoxides: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with sulfoxides and triethylamine are provided. The resultant carbon-isotope labeled acids, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method for PET studies... Agent: Ge Healthcare, Inc.

20080206148 - Method for radiographic targeting of malignant tumors and apparatus for focusing rays: A method and apparatus for immunoimaging and destruction of malignant tumors using immunoimaging agents comprising nanoclusters incorporating monoclonal antibodies that selectively bind to the cell membrane of tumor cells, and conjugated payloads comprising an encapsulated near-infrared (NIR) fluorescing crystal. The encapsulated fluorescing crystal compound provides excellent non-radiometric imaging of the... Agent: Ober / Kaler A Professional Corporation

20080206149 - Method, dye and medicament for staining the internal limiting membrane, epiretinal membrane, the vitreous and/or the capsule of an eye: The present invention concerns a method of staining the internal limiting membrane, the vitreous and/or the lens capsule of the eye as well as dyes and medicaments suitable for this method. Such dyes, medicaments and methods are needed in ophthalmic surgery, in particular in macular and/or cataract surgery and/or vitrectomy.... Agent: Leydig Voit & Mayer, Ltd

20080206153 - Copolymers for cosmetic agents, produced in the presence of polyfunctional chain transfer agents: The present invention relates to cosmetic and pharmaceutical compositions which comprise a copolymer with anionogenic and/or anionic groups which is obtainable by free-radical polymerization of a monomer mixture in the presence of a polyfunctional regulator with at least three functional regulating groups. The invention further relates to a method of... Agent: Connolly Bove Lodge & Hutz, LLP

20080206154 - Single-stranded antimicrobial oligonucleotides and uses thereof: The current invention is directed to oligonucleotide sequences isolated from a sequence designated rbl-1 [SEQ ID NO. 19] that either kill or inhibit growth, or prevent the production of endogenously expressed toxin, of microorganisms. These ssDNA sequences, identified through use of a screening method, appear to act as modulators of... Agent: Osha & Liang LLP / Cytogenix

20080206155 - Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses: A stable non-alcoholic foamable pharmaceutical emulsion composition includes an unctuous emollient, at a concentration of about 0.5% to about 49% by weight; at least one multi-active agent; at a concentration of about 0.5% to about 15% by weight; water; an effective amount of an active pharmaceutical agent having a degree... Agent: Wilmerhale/boston

20080206158 - Benzoic acid ester compounds, compositions, uses and methods related thereto: s

20080206157 - Cerebral protection with a xenon-containing gas: Xenon or xenon-containing gases and, where appropriate, an NO source are employed as medicament for cerebral protection. Cerebral protection is defined as reducing or preventing impairments of cerebral function of various causes, but especially secondary to perfusion impairments of unclear etiology. The medicament can be used for cerebral protection for... Agent: Connolly Bove Lodge & Hutz, LLP

20080206162 - Composition and methods for treating alzheimer's disease and other amyloidoses: A method of treating an amyloid disease in a patient or inhibiting the formation, deposition, accumulation, or persistence, of amyloid fibrils, amylin fibrils, or islet amyloid fibrils, and/or dissolving or disrupting pre-formed or pre-deposited amyloid fibrils in type II diabetes in a mammalian subject. In the method a therapeutically effective... Agent: Proteotech, Inc.

20080206159 - Compositions with modulating agents: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless... Agent: Wilmerhale/boston

20080206156 - Continuous spray scalp therapy and dispensing systems for same: The present invention relates to continuous spray medications involving the scalp, such as minoxidil, finesteride, copper peptides, DHT inhibitors and androgen receptor blockers, for example, in an amount sufficient to stimulate or maintain hair growth. The scalp medication is disposed within a pharmacologically acceptable carrier solution. In further embodiments, the... Agent: Duane Morris, LLP Ip Department

20080206163 - Derivatives of pyrimido[6, 1-a]isoquinolin-4-one: Compounds of general formula (I) wherein each of R1 and R2 independently represents a C1-6 alkyl or C2-7 acyl group; R5 represents a hydrogen atom or a C1-3 alkyl, C2-3 alkenyl or C2-3 alkynyl group; R6 represents a hydrogen atom or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, amino, C1-6... Agent: Edwards Angell Palmer & Dodge LLP

20080206161 - Quiescent foamable compositions, steroids, kits and uses thereof: The present invention relates to an emulsion steroid composition as a foamable vehicle in which the vehicle is stable or stabilized by the presence of at least one quiesence agent; therapeutical kit containing such composition; to methods of treatment using such composition; to methods of enhancing the stability of such... Agent: Wilmerhale/boston

20080206160 - Short bio-active peptides for cellular and immunological modulation: Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these... Agent: Howrey LLP-hn

20080206164 - Cosmetic composition comprising at least one cationic polyurethane and at least one vinyl pyrrolidone homo- or copolymer, and method of styling therewith: p

20080206165 - Single-use personal care products and kits comprising same: Single-use personal care products and kits comprising the same are disclosed. At least some of the single-use products include a pre-measured amount of a shaving composition.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080206166 - Oral soap composition for cleaning teeth: Provided herein is an oral soap composition comprising an orally-acceptable soap base effective to clean teeth that includes one or more natural oils, a saponifying agent and distilled water. The oral soap composition may be liquid or solid. Also provided are oral soap compositions comprising an essential oil for flavoring.... Agent: Dr. Benjamin Adler Adler & Associates

20080206167 - Oral soap composition for cleaning teeth: Provided herein is an oral soap composition comprising an orally-acceptable soap base gel effective to clean teeth that includes one or more natural oils saponified by a saponifying agent, e.g., potassium hydroxide or sodium hydroxide in distilled water. The oral soap composition may be liquid or solid. Also provided are... Agent: Benjamin Aaron Adler Adler & Associates

20080206171 - Conditioned medium and uses thereof: The invention relates to compositions containing an agent that has an irritant side effect and a conditioned cell culture medium and/or of an extract thereof, for use, e.g., in the treatment of signs of inflammation and/or of immune disorders, the medium being obtainable by contact with at least one culture... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080206170 - Creatine compositions for skin treatment: The present invention relates to the use of creatine compounds, such as, for example, creatine monohydrate, creatine pyruvate and creatine ascorbate, for the treatment of skin.... Agent: Lahive & Cockfield, LLP

20080206169 - Personal care composition: Personal care composition comprising at least one skin care active selected from the group consisting of acetyl glutamic acid, acetyl glutamine, acetyl methionine, acetyl tributyl citrate, acetyl triethyl citrate, acetyl tyrosine, adipic acid, alanine, arginine, arginine glutamate, benzophenone-3, camphor, gluconolactone, glucose, glycine, histidine hydrochloride, hydroxyproline, maltitol, phenylalanine, succinic acid, buffered... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080206168 - Personal care compositions: The deposition of a benefit agent on a substrate after treatment of the substrate with a personal care composition which has a viscosity of at least 50 mPa·s at 25° C. and comprises the benefit agent and a low molecular weight surfactant is improved when a water-soluble polymer is used... Agent: The Dow Chemical Company

20080206172 - Clear sunscreen gels and methods of use thereof: The present invention relates to an alcohol-free transparent sunscreen composition containing at least one chemical ultra-violet (UV) light absorber, at least one solvent and at least one diphenyl silicone elastomer gellant. Preferably, the solvent is selected from the group consisting of dimethicone, dicaprylyl carbonate, lauryl lactate, neopentyl glycol diheptanoate, glycerin,... Agent: The Estee Lauder Cos, Inc

20080206174 - Lustrous and scratch-resistant nail varnish through addition of silanes: e

20080206173 - Nail compositions in powdered form: A process for making up nails involving the steps of: (a) providing a first composition, in powder form, containing: (i) at least one colorant, in powder form; (ii) optionally, at least one film-forming polymer, in powder form; and (iii) optionally, at least one plasticizer; (b) providing a second composition containing:... Agent: L'oreal Usa/ Patent Department

20080206175 - Composition for skin whitening and wrinkle improvement comprising vaccinium uliginosum extract and method for preparation thereof: The present invention relates to a composition for the skin whitening and wrinkle improvement, comprising an extract of Vaccinium uliginosum as an active ingredient. The Vaccinium uliginosum extract has the effects of inhibiting and scavenging reactive oxygen species produced in skin tissue as a result of ultraviolet irradiation to the... Agent: Ked & Associates, LLP

20080206177 - Cosmetic composition comprising at least one cationic polyurethane and at least one polyethylene glycol ester, to be applied during hair dressing: e

20080206176 - Personal care composition comprising aminosilicone and naturally derived cationic polymers:

20080206178 - Viscoelastic cosmetic composition for styling and conditioning of human hair: The sensory attributes of cosmetic compositions are very important to form positive consumer's perception of the product. The sensory attributes can vary significantly depending on the formulation employed. In the present invention, a particularly beneficial balance of attributes was attained to create a usable viscoelastric composition that can be poured... Agent: Melvin I. Stoltz, Esq.

20080206179 - Personal care compositions containing cationic synthetic copolymer and a detersive surfactant: e

20080206180 - Hair and/or scalp care compositions incorporating amino-oxo-indole-ylidene compounds: A hair and/or scalp treatment composition comprising an amino-oxo-indole-ylidene compound of general formula (I): (I) formula should be here in which: R1, R2, R3 and R4 are each, independently, hydrogen or a monovalent organic group selected from alkyl, alkenyl, alkynyl, aryl, alkylenearyl, cycloalkyl, cycloalkenyl, and heterocyclyl.... Agent: Unilever Patent Group

20080206181 - Hair treatment compositions containing sophora alkaloids: h

20080206184 - Chemically modified protein compositions and methods: The present invention broadly relates to the field of protein modification and more specifically, water soluble block polymers, their attachment to drugs, and methods of making and use thereof.... Agent: Marshall, Gerstein & Borun LLP

20080206182 - Conjugates of a polymer and a protein linked by an oxime group: The present invention relates to polymers functionalized by an aminooxy group or a derivative thereof, conjugates, wherein the functionalized polymers are covalently coupled with a protein by an oxime linking group, a process for preparing the functionalized polymers, a process for preparing the conjugates, functionalize polymers as obtainable by the... Agent: Fish & Richardson P.c.

20080206183 - Method of preparing grafted polylysine dendrimers: The use of monomers of active a-amino acids for the preparation of hydrophobic polypeptides in the form of precipitates, whereby the polypeptides result from the polymerization of the aforementioned monomers of active a-amino acids in an aqueous solvent and can be resolubilized in the solvent.... Agent: Young & Thompson

20080206185 - Personal care composition comprising a silicone elastomer: e

20080206187 - Method for treating a neoplastic disorder: A method for treating a neoplastic disorder in a subject includes administering to the neoplastic cells a neoplastic cell-sensitizing composition including a poly(ethylene oxide)-poly(propylene oxide) copolymer. The poly(ethylene oxide)-poly(propylene oxide) copolymer can sensitize the neoplastic cells to hyperthermia. Energy can be applied to the neoplastic cells to heat and ablate... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20080206186 - Pro-angiogenic polymer scaffolds: A pro-angiogenic porous polymer scaffold is disclosed. The polymer has at least 20 mol-% monomeric subunits containing acidic functional groups, and has a porosity of at least 40%. The pores in the scaffold are interconnected. A method of making such a scaffold using a novel adaptation to the traditional solvent... Agent: Borden Ladner Gervais LLP Anne Kinsman

20080206188 - Therapeutic delivery system comprising a high molecular weight peg-like compound: The present invention provides a system for delivering a wide range of chemical and biological therapeutics, including protein therapeutics, via transepithelial routes. The system comprises a high molecular weight polyethylene glycol-like (HMW PEG-like) compound for use with a therapeutic compound. Optionally, the system comprises a composition containing one or more... Agent: Marshall, Gerstein & Borun LLP

20080206192 - Combination therapy: The invention provides combination treatments with IL-21, analogues and derivatives thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080206191 - Compounds for the treatment of hepatitis c: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080206190 - Glycosylated il-7, preparation and uses: The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080206193 - Method for treatment and management of thyroid cancer using immunomodulatory compounds: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20080206189 - Method of treating cancer by administering conjugates comprising human il-18 and substitution mutants thereof: Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and substitution mutants thereof retain biological activity. These conjugated cytokines demonstrate enhanced and unexpected biological properties when compared to the corresponding unconjugated cytokines.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080206194 - Method for the treatment of breast cancer: A method for inducing ERα expression in cancer cells in a subject affected with cancer cells which are ERα (−) is disclosed. The method involves administering to the subject an effective amount of a PPARγ antagonist alone or in combination with anti-estrogen therapy.... Agent: M. Carmen & Associates, Pllc

20080206195 - Compositions and methods for treating disorders associated with abnormal phosphate metabolism: The present invention uncovers that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause familial tumoral calcinosis (FTC). Methods and pharmaceutical compositions useful for treating disorders associated with abnormal phosphate metabolism are provided. Specifically, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on... Agent: Martin D. Moynihan Prtsi

20080206196 - Differentiation of cord blood into neural like cells, and method to treat neurological condition patients: The invention discloses a method of expansion and differentiation umbilical cord blood cells into neural-like cells in clinic grade, the cell preparation and herein the method for treating neurological condition in human.... Agent: Lixian Jiang

20080206199 - Chimeric herpes viruses and uses thereof: Disclosed herein are chimeric herpesviruses as well as methods of making and using such chimeric herpesviruses. The chimeric viruses comprise two nucleic acid sequences, one from a herpesvirus and one from a different virus. The herpesvirus nucleic acid sequence is a modified protein kinase R (PKR) evasion gene. The second... Agent: Fish & Richardson P.c.

20080206198 - Compounds and methods for pharmico-gene therapy of epithelial sodium channel associated disorders: Agents and methods to alter epithelial sodium channel (ENaC) activity.... Agent: Schwegman, Lundberg & Woessner, P.a.

20080206197 - Metabolically activated recombinant viral vectors and methods for their preparation and use: Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one... Agent: Morrison & Foerster LLP

20080206200 - Selected endothelial progenitor cells and methods for use: The present invention is a method for preparing a substantially pure population of endothelial progenitor cells wherein said cells express Flk-1, CD34, α5β1 integrin fibronectin, and vWF and exhibit an adherent phenotype and methods for using the same to decrease the severity of lung injury, prevent pulmonary edema, restore endothelial... Agent: Jane Massey Licata Licata & Tyrrell P.c.

20080206210 - Drugs for the prevention or treatment of immunodeficiencies, autoimmune diseases or for the induction of immune tolerance: The invention relates to the use of viral vectors able to stably integrate into the genome of thymic stromal cells, or of intrathymic lymphocytes or lymphocytes precursors, for the manufacture of a medicine intended for intrathymic administration in the frame of the prevention or treatment of genetic immunodeficiencies, acquired immunodeficiencies,... Agent: Young & Thompson

20080206211 - Composition containing a cell culture medium: Composition containing a conditioned cell culture medium or an extract thereof, said medium being able to be obtained by contact with at least one culture of digestive tract cells and at least one probiotic microorganism. It also relates to the use of conditioned culture medium for improving skin homeostasis, etc.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080206213 - Method for reducing or preventing systemic inflammation: The present invention is directed to a novel method for treating or preventing systemic inflammation in a subject. The method administering to the subject a therapeutically effective amount of inactivated LGG.... Agent: Bristol-myers Squibb Company - Mead Johnson

20080206212 - Method for the utilization of and product containing inactivated probiotic: A novel method and product utilizing or containing one or more inactivated probiotics.... Agent: Bristol-myers Squibb Company - Mead Johnson

20080206214 - Inhibition of pathogens by probiotic bacteria: Compositions containing a lactic acid-producing bacterial strain, e.g., Bacillus coagulans for inhibition of pathogenic bacterial infections. Spores or extracellular products produced by the bacterial strains are also useful as inhibitory agents.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080206215 - Apparatus and method for treatment of microorganisms during propagation, conditioning and fermentation: A method of reducing undesirable microorganism concentration, promoting desirable microorganism propagation/conditioning, and increasing desirable microorganism efficiency in an aqueous fluid stream includes (a) introducing a quantity of fermentable carbohydrate or cellulose to an aqueous fluid stream, (b) introducing a quantity of desirable microorganism to the aqueous fluid stream, (c) generating... Agent: Mcandrews Held & Malloy, Ltd

20080206202 - Methods for application of endogenous or exogenous stem/progenitor or their progeny for treatment of disease: We propose here that endogenous stem/progenitor cells of the developing or adult nervous system be genetically modified in situ, to express therapeutically advantageous gene products. Furthermore, we propose here that endogenous or other exogenous stem cells or their progeny be genetically modified when appropriate to express advantageous gene products (and/or... Agent: Heller Ehrman LLP

20080206201 - Recombinant newcastle disease virus: The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding... Agent: Millen, White, Zelano & Branigan, P.c.

20080206206 - Bone marrow-derived neuronal cells: Bone marrow stromal cells (BMSC) differentiate into neuron-like phenotypes in vitro and in vivo, engrafted into normal or denervated rat striatum. The BMSC administered into the ventricle did not remain localized to the site of the graft, but migrated throughout the brain and integrated into specific brain regions in various... Agent: The Luther Law Firm, Plc

20080206205 - Cd34(+) cells and their methods of use: A CD34(+) cell line, which can be found in human lymph nodes, called CD34dimCD45RA(+)integrinβ7bright. Methods of isolating the novel cell type from tissue and methods of its use are also provided.... Agent: Calfee Halter & Griswold, LLP

20080206208 - Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissues: The invention concerns cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue, methods for preparing them and their use in regeneration of hematopoietic lines and cardiac and skeletal muscular tissues, in particular for treating genetic or acquired hemopathies, myopathies and cardiomypathies.... Agent: Alston & Bird LLP

20080206204 - Human parthenogenetic stem cells: The invention provides a method for establishing pluripotent cell lines from human parthenotes, the uses of said cell lines for producing differentiated cells or tissues and for therapeutic applications especially in regenerative medicine.... Agent: Arent Fox LLP

20080206207 - Intracoronary device and method of use thereof: Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems.... Agent: Squire, Sanders & Dempsey L.l.p.

20080206203 - Method for inhibiting tumor metastasis: A leukotriene C4 and D4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, thereby preventing tumor cell extravasation.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080206209 - Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated... Agent: Nixon Peabody LLP - Patent Group

20080206217 - Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active... Agent: Womble Carlyle Sandridge & Rice, Pllc

20080206218 - Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active... Agent: Womble Carlyle Sandridge & Rice, Pllc

20080206216 - Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active... Agent: Womble Carlyle Sandridge & Rice, Pllc

20080206220 - 2031 oxidoreductase: e

20080206219 - Novel indications for transforming growth factor-beta regulators: Methods, compounds and compositions for the modulation of TGF-β are disclosed wherein the vascular permeability in a subject is altered. The compounds can be antagonists or agonists, and can be oligonucleotides, antisense oligonucleotides, small molecules, antibodies, and the like. Compounds that modulate TGF-β, regulate TGF-β bioavailabililty, or the configuration and... Agent: Fenwick & West LLP

20080206221 - Nicotinamide riboside kinase compositions and methods for using the same: The present invention relates to isolated nicotinamide riboside kinase (Nrk) nucleic acid sequences, vectors and cultured cells containing the same, and Nrk polypeptides encoded thereby. Methods for identifying individuals or tumors susceptible to nicotinamide riboside-related prodrug treatment and methods for treating cancer by administering an Nrk nucleic acid sequence or... Agent: Licata & Tyrrell P.c.

20080206222 - Preventive/therapeutic composition for free radical disease: A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080206223 - Treatment of pompe's disease: The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080206224 - Muscle contraction treatment utilizing botulinum toxin: The invention provides for the use of a botulinum toxin to treat contracture, such as muscle contracture, in patients by transdermal administration of the botulinum toxin.... Agent: Allergan, Inc.

20080206226 - Agent for promoting osteogenesis and/or inhibiting bone resorption: Provided is a novel agent for promoting osteogenesis and/or inhibiting bone resorption, which: can be directly taken from daily meals by mouth for long periods without any trouble in taste; directly impart a promoting effect on osteogenesis and an inhibiting effect on bone resorption to the bone; and can be... Agent: Young & Thompson

20080206225 - Closed container comprising an activated factor vii polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit: The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080206227 - Factor vii conjugates for selectively treating neovascularization disorders: Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080206228 - Pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers... Agent: Hedman & Costigan P.c.

20080206232 - Compositions and methods for modulating pgc-1beta to treat lipid-related diseases and disorders: The present invention provides methods for treating lipid-related diseases and disorders, e.g., hyperlipidemia, hyper-triglyceridemia, hypercholesterolemia, cardiovascular disease, obesity, and type II diabetes, and for modulating lipid biosynthesis, lipid transport, plasma triglyceride levels and/or plasma cholesterol levels, by modulating the expression or activity of PGC-1β. Methods for identifying compounds which are... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080206235 - Compositions and methods for stimulating an immune response: Compositions and methods for the stimulating, enhancing or promoting an immune response in a host are provided. One embodiment provides methods and compositions for stimulating, enhancing, or promoting an immune response in a host by administering an effective amount of a B7-H4 antagonist, preferably sH4 or variant thereof. Compositions of... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080206234 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080206231 - Compositions and methods for treating disease: The present invention discloses for the first time that the insulin receptor (IR) is a target of Herstatin, which modulates IR and IR-mediated intracellular signaling. In preferred aspects, Herstatin binds at nM concentrations to cell-surface IR, up-regulates basal IR expression by several-fold, induces the accumulation of pro-IR, and stimulates insulin... Agent: Davis Wright Tremaine, LLP/seattle

20080206233 - Heavy chain and single domain antibodies: The present invention relates to heavy chain immunoglobulins or fragments thereof of the VHH or VNAR type, or domain antibodies (dAbs) of the heavy or light chains of immunoglobulins or fragments thereof, suitable for use in the management of infections, in particular of the gastrointestinal tract. The present invention also... Agent: Morgan Lewis & Bockius LLP

20080206229 - Modified antibodies recognizing receptor trimers or higher multimers: The present invention provides tandem diabodies and triabodies against TRAIL receptors, wherein the tandem diabodies and triabodies exhibit greater cytotoxicity as single molecules than whole IgG antibodies. The present invention demonstrates that antibodies that enhance polymerization are useful when aiming to induce cell apoptosis via receptors such as TRAIL receptors,... Agent: Klarquist Sparkman, LLP

20080206230 - Peptides derived from human bplp protein, polynucleotides coding for said peptides and antibodies directed against said peptides: The present invention also relates to polynucleotides coding for said peptides and to antibodies directed against said peptides. Furthermore, the present invention relates to diagnostic and therapeutic uses of human BPLP protein and inhibitory peptides derived therefrom, polypeptides coding for human BPLP protein or peptides derived therefrom as well as... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080206236 - Polyclonal antibody product: The present invention relates to a composition comprising two or more sets of target-specific recombinant polyclonal antibodies, each set being capable of binding to a distinct target, wherein said distinct targets are related to diseases, which may be treated or prevented by the use of antibodies, and wherein said composition... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080206237 - Synergistic combination of xolair/omalizumab/e25 with immunosuppressive agent: The present invention provides a pharmaceutical composition comprising an Anti-IgE Antibody and at least one further immunosuppressive agent, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous,... Agent: Novartis Corporate Intellectual Property

20080206238 - Angiogenesis-inhibiting chimeric protein and the use: The present invention is directed to DNA sequence encoding angiogenesis-inhibiting recombinant chimeric protein, the chimeric protein per se, the pharmaceutical use of the chimeric protein, and to the pharmaceutical composition containing the recombinant protein and the formulation thereof.... Agent: Nath & Associates

20080206240 - Antilymphocyte antibody induction: An immunosuppressive treatment combining a S1 P receptor modulator, one or more immunosuppressive drug(s) and an antilymphocyte antibody in the course of the treatment of a transplant recipient prolongs the survival of a transplant allograft.... Agent: Novartis Corporate Intellectual Property

20080206239 - Human antibodies and proteins: The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.... Agent: Brooks Kushman P.c.

20080206242 - Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies: A method of treating Th2-mediated conditions, e.g., atopic conditions, e.g., atopic asthma and/or atopic dermatitis, using effective amount of an antibody that targets CD30, where the antibody has at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080206243 - Methods for treating kidney disorders: Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR agonist, e.g., a Flt1 agonist to a subject. The agonists are composed of compositions comprising VEGFR agonists, e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents... Agent: Genentech, Inc.

20080206241 - Methods of treating chronic inflammatory diseases using a gm-csf antagonist: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA... Agent: Townsend And Townsend And Crew, LLP

20080206244 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080206245 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080206247 - Glycoprotein vi fusion proteins: m

20080206246 - Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080206249 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080206250 - Compositions and methods for the therapy and diagnosis of breast cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group Pllc

20080206248 - Mutations in erbb2 associated with cancerous phenotypes: The invention relates to mutations in ErbB2 gene products. The mutations described are identified in human tumours of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for the diagnosis of cancer, cancerous cells or a predisposition to cancer in human subjects, selection... Agent: Frommer Lawrence & Haug

20080206251 - Methods and compositions to treat and detect misfolded-sod1 mediated diseases: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1)... Agent: Bereskin And Parr

20080206252 - Novel polypeptides, and nucleic acids encoding the same: An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to the sequence SEQ ID NOS:2, 4, 6 or 8, polynucleotides encoding these peptides, and antibodies to the polypeptides are useful in treating cancers.... Agent: Merchant & Gould Pc

20080206253 - Method for preventing or treating pain in a mammal: Methods are provided for preventing or treating pain in a mammal comprising administering an inhibitor of p38β MAP kinase in a therapeutically effective amount to the mammal in need thereof.... Agent: Woodcock Washburn LLP

20080206254 - Novel anti-factor viii antibodies: The present invention relates to new antibodies and fragments and derivatives thereof, which are particularly suited for the characterization of the structure and function of Factor VIII (FVIII) of the coagulation pathway, for the design of therapeutic strategies for eradication of FVIII inhibitors and for the use as a medicament... Agent: Clark & Elbing LLP

20080206255 - Antibody cancer immunotherapy: A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an... Agent: Akerman Senterfitt

20080206257 - Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor: The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment... Agent: Ladas & Parry

20080206256 - Treatments for cancer: The present invention provides methods for reducing tumor survival, expansion, and metastasis. In particular, the invention provides methods for reducing pancreatic tumor survival, expansion, and metastasis. The invention also provides agents for use in the methods, particularly agents that reduce the level or activity of connective tissue growth factor (CTGF),... Agent: Fibrogen, Inc. Intellectual Property Department

20080206258 - Novel tetrahydropyridothiophenes: e

20080206259 - Prevention and treatment of sepsis: Compositions and methods are described for treatment of sepsis in animals, including humans. Unique and specific combinations of polyclonal antibodies directed to cytokines are shown to have a beneficial effect in animal models predictive of human therapy.... Agent: Peter G. Carroll Medlen & Carroll, LLP

20080206260 - Chimeric tbp-toxin proteins as mucosal adjuvants for vaccination against neisseriae: Chimeric fusion proteins comprising Neisseria transferrin binding proteins (Tbps) from, for example, N. gonorrhoeae and/or N. meningitidis are provided. The fusion proteins elicit an antibody response in the mucosa of the urogenital and/or oropharynx tract, as well as in the serum. The resulting serum antibodies are cross-bactericidal against heterologous bacterial... Agent: Whitham, Curtis & Christofferson & Cook, P.c.

20080206262 - Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr): The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.... Agent: Chalker Flores, LLP

20080206263 - Methods and compositions for prognosing, detecting, and treating age-related macular degeneration: The invention provides methods and compositions for determining whether a subject is at risk of developing age-related macular degeneration, for example, the wet or neovascular form of age-related macular degeneration. The method involves determining whether the subject has a protective variant and/or a risk variant at a polymorphic site in... Agent: Goodwin Procter LLP Patent Administrator

20080206261 - Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof: Methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of IBD. In particular, the present invention is directed to the identification of novel targets that are IBD differential markers. The present invention is further directed to methods of high-throughput screening for test compounds... Agent: Fitzpatrick Cella (wyeth)

20080206266 - Carbohydrate ligands specific for mhc molecules: The present invention provides methods to isolate a carbohydrate ligand or a leczyme and to identify a carbohydrate ligand or a leczyme that modifies the function of a cell and to obtain such functionally modified cells. The invention further provides methods to modify a cell to express a carbohydrate ligand... Agent: Fish & Associates, Pc Robert D. Fish

20080206264 - Constrained hiv v3 loop peptides as novel immunogens and receptor antagonists: The present invention provides constrained peptides and other organic molecules, that mimic the three dimensional characteristics of the HIV-1 V3 loop peptide when bound by a highly potent human neutralizing monoclonal antibody specific for a V3 conformational epitope, which structure is determined by NMR. Methods for screening for, and designing... Agent: Mckenna Long & Aldridge LLP

20080206265 - Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.... Agent: Keown & Zucchero, LLP

20080206268 - Ha-1 epitopes and uses thereof: Peptide sequences constituting T-cell epitopes of minor Histocompatibility antigen, HA-1. HA-1 is associated with Graft versus Host Disease. The peptides and their derivatives find many uses, for instance, in bone marrow transplantation, organ transplantation and in treatment of leukemia and non-hematopoietic tumors. The peptide and/or its derivatives can be incorporated... Agent: Allen C. Turner Traskbritt, Pc

20080206267 - Inactivation of genes of the mep pathway: The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes. The derivatives can also be enriched by using enzyme inhibitors. The enriched... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080206269 - Bacterial pheromones and uses thereof: RP-factors, their cognate receptors, convertases, respective genes and inhibitors or mimetics thereof are described. In particular, antibodies, pharmaceutical compositions and (therapeutic, diagnostic) methods based on the RP-factors and their receptors/convertases are described... Agent: Edwards Angell Palmer & Dodge LLP

20080206270 - Enhancing class i antigen presentation with synthetic sequences: The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration... Agent: Dla Piper Us LLP

20080206271 - Fusion antigen used as vaccine: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to... Agent: Ipc Intellectual Property Connections, Inc.

20080206275 - Composition for treating obesity and method of using the same: The present invention provides a composition for a medicinal or health effect of a treatment of liver fat and body fat, a reduction of blood pressure, an increase of the energy expenditure rate, a reduction of inflammatory C-reactive proteins and a reduction of plasma aminotransferase enzymes, comprising an effective amount... Agent: Kramer & Amado, P.c.

20080206274 - Composition of marine botanicals to provide nutrition to aging and environmentally damaged skin: The present invention relates to novel methods and compositions comprising marine botanicals for treating aged, mature, nutritionally-compromised, or environmentally-damaged skin. These methods and compositions provide improvements in the skin's visual appearance, physiological functions, clinical properties, and biophysical properties.... Agent: Fulbright & Jaworski L.l.p.

20080206273 - Cosmetic product comprising a seaweed extract, in particular carrageen: The present invention resides in a cosmetic product comprising a surfactant, glycerine monopropylene glycol, and a seaweed extract.... Agent: Westman Champlin & Kelly, P.a.

20080206272 - Method for repelling pests with an insect repellent composition based on garlic: The Invention relates to a method for repelling pests, in particular insects, larvae, spiders or aphids, from a plant, in particular from a tree or bush, wherein the method comprises making a hole down to the root zone of a plant and putting a natural insect repellent composition that contains... Agent: Foley And Lardner LLP Suite 500

20080206276 - Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-γ-glutamic acid (such as γDLPGA) polypeptides of S. epidermidis, or related staphylococci that express a γPGA polypeptide. The γPGA conjugates elicit an effective immune... Agent: Klarquist Sparkman, LLP

20080206277 - Isolated nucleic acid molecule encoding a neurotrophic growth factor: There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid... Agent: Hunton & Williams/new York Intellectual Property Dept.

20080206278 - Vaccine: Provided herein are methods for immunizing children under six months of age by administering to the child a pharmaceutical composition comprising at least one antigen derived from an influenza virus.... Agent: Sanofi Pasteur, Inc.

20080206279 - Vaccines against west nile virus: The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to... Agent: Trask Britt

20080206280 - Vaccine for activating helper function of cd8+ tcells: The invention provides compositions and methods for treating or preventing a target disease in a mammal by induction of memory T cells. The methods comprise (1) administering a sensitizing composition comprising a non-target antigen to a patient; and (2) administering a therapeutic composition comprising a non-target antigen and a target... Agent: Leydig Voit & Mayer, Ltd

20080206281 - Method for producing storage stable viruses and immunogenic compositions thereof: The invention relates to methods for producing storage stable virus compositions. In certain embodiments, the invention relates to one or more formulations and process steps which result in storage stable virus compositions, wherein the composition is storage stable as a lyophilized solid composition or a frozen liquid composition.... Agent: Wyeth Patent Law Group

20080206282 - Chimeric lyssavirus nucleic acids and polypeptides: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080206283 - Vaccine against sars: The present invention provides nucleotide sequences from SARS (Serve Acute Respiratory Syndrome) coronavirus genomes, as well as the applications of the partial fragments thereof in preparing DNA vaccine or expressing corresponding proteins. Furthermore, the present invention also provides the uses of said proteins in preventing and treating diseases, and preparing... Agent: Scully Scott Murphy & Presser, Pc

20080206284 - Agent for treating allergic or hypersensitivity condition: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside activity affects an allergic condition... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080206285 - Compositions and methods for treatment and prevention of leishmaniasis: Taught herein are therapeutic pharmaceutical compositions (vaccines) and methods for preventing or treating leishmaniasis and infections mediated by intracellular pathogenic micro-organism in mammals and in particular in humans, members of the dog, cat and horse family. The pharmaceutical compositions comprise composition of matter produced by from Leishmania sp. amastigotes and/or... Agent: Matthias Scholl

20080206286 - Cancer stem cell antigen vaccines and methods: Method of stimulating an immune response (e.g., to treat cancer) include administering to a patient a composition including dendritic cells that present cancer stem cell antigens. Compositions including cancer stem cell antigens are also provided herein.... Agent: Fish & Richardson Pc

20080206289 - Prostate cancer and melanoma antigens: Methods for identifying a human subject as a candidate for further prostate cancer or melanoma examination are disclosed. Also disclosed are methods for determining whether an immune therapy has elicited a tumor-specific immune response in a prostate cancer or melanoma patient. Further disclosed are kits that can be used to... Agent: Quarles & Brady LLP

20080206288 - Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines: The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which... Agent: Moore & Van Allen Pllc

20080206287 - Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands: Cyclosporin A has been discovered to sensitize cancers resistant to TNF-family death receptors such as TRAIL and Fas to ligand-mediated apoptosis. Therefore, compositions that include cyclosporin A are useful in treating such cancers.... Agent: Biotechnology Law Group C/o Portfolioip

20080206290 - Cosmetic combination product for improving appearance: A cosmetic combination product, wherein the product comprises at least two components selected from (a) one or more dietary supplements, (b) one or more cosmetic preparations for topical application to human skin, and (c) one or more patches for adhesion to human skin. Each of the selected components (a) to... Agent: Greenblum & Bernstein, P.L.C

20080206292 - Cosmetic method for targeting of wrinkles: A subject-matter of the invention is a cosmetic method for caring for wrinkled skin, for the purpose of softening the wrinkles, comprising the successive stages: (a) of topical application to the wrinkled areas of a first composition including a pulverulent phase comprising porous particles which comprise at least one antiwrinkle... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080206291 - Polyurethane and polyurea microcapsules: The present invention relates to a perfuming ingredient for body-care, detergents or softeners type consumer products that is made of microcapsules having a mean diameter of >1 to 500 μm with a guanidine-based polyurea or polyurea/polyurethane wall that contain a perfume and to the products that contain such perfuming ingredients... Agent: Winston & Strawn LLP Patent Department

20080206293 - Absorbent substrate with a non-leaching antimicrobial activity and a controlled-release bioactive agent.: This invention relates to antimicrobial wound dressings having a non-leaching antimicrobial activity, releasable antimicrobial and antiprotease agents, and a controlled-release bioactive agent such as doxycycline. The Wound dressing material is absorbent and acts as a substrate for antimicrobial and antiprotease agents as well as bioactive agents. More generally, this invention... Agent: Elman Technology Law, P.c.

20080206294 - Naphthalene derivatives as termite repellents and toxicants: Several derivatives of naphthalene, including 1′-acetonaphthone, 2′-acetonaphthone, 1-methoxynaphthalene, and 2-methoxynaphthalene, were discovered to be effective toxicants and repellents of termites, and resulted in significant reduction in termite feeding activity. For example, 2′-acetonaphthone was found to be an effective repellent and feeding deterrent of termites. Termites exposed to concentrations as low... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20080206295 - Formulations based on 3-iodo-2-propynyl butyl carbamate: Formulations in water suspension of microcapsules based on 3-iodo-2-propynyl butyl carbamate (IPBC) comprising (parts by weight): (a) 10-60 parts of polymeric microcapsules comprising inside them IPBC and a synergizing agent formed of one or more alkylbenzenes having a number of carbon atoms from 9 to 20: (2) 1-5 parts of... Agent: Arent Fox LLP

20080206296 - Injectable calcium-phosphate cement releasing a bone resorption inhibitor: The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof.... Agent: Stites & Harbison Pllc

20080206297 - Porous composite biomaterials and related methods: Synthetic composite materials for use, for example, as orthopedic implants are described herein. In one example, a composite material for use as a scaffold includes a thermoplastic polymer forming a porous matrix that has continuous porosity and a plurality of pores. The porosity and the size of the pores are... Agent: Hanley, Flight & Zimmerman, Llc

20080206307 - Biologically absorbable coatings for implantable devices and methods for fabricating the same: Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising a biologically degradable, biologically erodable, and/or biologically resorbable ABA or AB block copolymer. A biologically active agent can be conjugated to the block copolymer.... Agent: Squire, Sanders & Dempsey LLP

20080206301 - Bone void fillers and methods of making the same: The invention relates to a material for use as bone void filler comprising soluble keratin protein. The material may be in the form of a putty, gel or emulsion. Additional components may be added to the material to improve handling characteristics and bone enhancement capabilities. The material may be formulated... Agent: Holland & Hart, LLP

20080206302 - Cell-free graft: e

20080206298 - Enhanced biological autologous tissue adhesive composition and methods of preparation and use: The invention includes a composition useful for preparing a tissue sealant for use on a patient, comprising: autologous fibrinogen, an activating agent and at least one supplement. The invention includes a method of treating a disc having at least one defect, comprising: introducing a composition into the disc, wherein the... Agent: O'keefe, Egan, Peterman & Enders LLP

20080206305 - Implantable barrier device: A barrier device is formed of a barrier component that can exhibit anti-inflammatory properties, non-inflammatory properties, and/or adhesion-limiting properties, as well as generate a modulated healing effect on injured tissue. The barrier component can be a non-polymeric cross-linked gel derived at least in part from a fatty acid compound, and... Agent: Lahive & Cockfield, LLP

20080206304 - Medical devices having polymeric regions based on styrene-isobutylene copolymers: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions. These polymeric regions, in turn, contain one or more polymers, at least one of which is a copolymer that includes a styrene monomer and an isobutylene monomer. Moreover,... Agent: Mayer & Williams Pc

20080206299 - Method for recovering minerals from bone and use of same: Systems and methods for recovering bone minerals from bone are provided in which bone minerals are separated from bone, and the separated bone minerals with natural bone mineral inorganic moieties are isolated. Also provided are implantable hydroxyapatite materials that are at least partially derived from bone and include natural bone... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080206306 - Poly(ester amide) block copolymers: Provided herein is a copolymer that includes a soft block (A) and a hard block (B) comprising a tyrosine di-peptide. The copolymer can be any of AB, ABA or BAB type block copolymers. The soft block can include a PEA polymer. A coating formed of the copolymer may also include... Agent: Squire, Sanders & Dempsey LLP

20080206303 - Prolonged release formulations comprising anastrozole: The present invention relates to slow release anastrozole formulations, more particularly to in situ gelling formulations comprising a polylactide polymer or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer, and processes for... Agent: Astrazeneca R&d Boston

20080206300 - Shaped article: The shaped article is obtained via a cementitious reaction of a particulate composition reactive with water, whereby said reaction is obtained between said composition and an aqueous, liquid or gaseous phase. The particles of the shaped article are present in the form of interlocked particles, whereby the interlocking of said... Agent: Schwegman, Lundberg & Woessner, P.a.

20080206308 - Hydrogel porogents for fabricating biodegradable scaffolds: Hydrogel microparticles with entrapped liquid are used as the porogen to reproducibly form interconnected pore networks in a porous scaffold. In one embodiment, a biodegradable unsaturated polymer, a crosslinking agent, and a porogen comprising biodegradable hydrogel microparticles are mixed together and allowed to form a porous scaffold in an mold... Agent: Quarles & Brady

20080206309 - Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia: A method of treating menorrhagia and/or dysmenorrhoea in a patient the method comprising administering to the patient an antagonist of a prostaglandin EP2 and/or EP4 receptor. Preferably the patient is a human female.... Agent: Nixon Peabody LLP - Patent Group

20080206310 - Regimens for controlled drug delivery devices for contraception: The subject invention provides for new regimens for contraceptive dosage forms.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080206313 - Compositions useful especially for treatment or prevention of metabolic syndrome: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080206311 - Sucrase activity inhibitor, glucoamylase activity inhibitor and food and feed containing the same: The invention provides a sucrose activity inhibitor and a glucoamylase activity inhibitor comprising one or more saccharides selected from the group consisting of palatinose, trehalulose and palatinit. Further, the invention provides a food or feed comprising the sucrose activity inhibitor and/or the glucoamylase activity inhibitor.... Agent: Oliff & Berridge, Plc

20080206312 - Therapeutic morpholino-substituted compounds: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers... Agent: Pepper Hamilton LLP

20080206315 - Drug containing adhesive preparation: The present invention provides an adhesive preparation having an adhesive layer on at least one surface of a support, wherein the adhesive layer comprises a first synthetic rubber having a viscosity average molecular weight of 1,600,000-6,500,000, a drug, an organic liquid component and a tackifier. The present invention further provides... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080206314 - Transdermal delivery systems: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form... Agent: Durect Corporation Thomas P. Mccracken

20080206316 - Chromium-fatty acid compounds and methods of making and using thereof: Disclosed are compounds comprising one or more chromium atoms bonded to one or more fatty acids. Also disclosed are nutritional supplements, pharmaceutical formulations, delivery devices, and foodstuffs comprising the disclosed compounds. Methods of using the disclosed compounds and compositions to improve health are also disclosed.... Agent: Needle & Rosenberg, P.c.

20080206319 - Hexosylceramides as adjuvants and their uses in pharmaceutical compositions: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control... Agent: Whitham, Curtis & Christofferson & Cook, P.c.

20080206317 - Ternary non-lamellar lipid compositions: The present invention provides a particulate composition including; a) at least 50 % of at least one structure forming amphiphile, b) 0 to 40% of at least one structure swelling amphiphile, and c) 2 to 20% of at least one dispersion stabilising polymeric amphiphile, where all parts are by weight... Agent: Nixon & Vanderhye, Pc

20080206318 - Therapeutic compositions that alter the immune response: The invention is therapeutic methods and compositions that alter the immunogenicity of the host.... Agent: Ropes & Gray LLP

20080206320 - Composition comprising at least one 15-pgdh inhibitor: The invention relates to a cosmetic composition containing at least one 15-hydroxy-prostaglandin dehydrogenase inhibitor and cosmetically acceptable excipients. It also relates to a method of cosmetic treatment for promoting the growth and/or preventing or delaying the loss of hair, and the use of a 15-hydroxyprostaglandin dehydrogenase inhibitor for the preparation... Agent: Buchanan, Ingersoll & Rooney Pc

20080206321 - Oral drug delivery system: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.... Agent: Thomas P. Mccracken Durect Corporation

20080206322 - Pharmaceutical multiparticulate composit ion comprising mycophenolic acid or myco phenolate sodium and combination compositions with rapamycin: The present invention relates to a novel composition, e.g. of mycophenolic acid, a salt or a prodrug thereof, in a modified release form.... Agent: Novartis Corporate Intellectual Property

20080206325 - Encapsulated active ingredients, methods of preparation and their use: The present invention relates to particles that include an active ingredient that is encapsulated first by coacervation, and then by a glassy matrix. The glassy matrix includes 3-50 wt % of a hydrophobically modified starch, and 50-97 wt % of a starch hydrolysate. The particles are useful for encapsulating active... Agent: Winston & Strawn LLP Patent Department

20080206324 - Pellets having an active compound matrix and a polymer coating, and a process for the production of the pellets: An active compound-containing pellet has a polymer coating of an anionic (meth)acrylate copolymer and a pharmaceutically active substance, embedded in a polymer matrix of one or more polymers, a particle size in the range from 300 to 1100 μm, a friability of at most 0.1%, measured using 200 g of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080206323 - Soft gelatin capsules: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.... Agent: Jay S. Cinamon Abelman, Frayne & Schwab

20080206326 - Production process for nsaid-containing lozenges, their compositions, their medicinal use: A process for producing a pharmaceutical lozenge formulation comprising the steps of: (a) providing a liquid composition comprising a salt of a non-steroidal anti-inflammatory drug (NSAID salt) and a solvent system, (b) providing a molten lozenge-forming composition, (c) mixing the liquid composition with the molten lozenge-forming composition, and, (d) forming... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080206327 - Solid dosage formulations containing weight-loss drugs: An orally disintegrating tablet which can be chewed or disintegrated by contact with saliva and containing weight-loss drugs for weight control in humans, especially in children and adolescents, is disclosed.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080206328 - Hypocholesterolemic compositions comprising a statin and an antiflatulent agent: The present invention relates to hypocholesterolemic compositions comprising statins plus antiflatulent agents. In particular the compositions of the present invention comprise a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, whether in free form or as pharmaceutically acceptable salts and hydrates thereof,... Agent: Birch Stewart Kolasch & Birch

20080206329 - Modified release ciprofloxacin compositions: Controlled release tablets comprising ciprofloxacin, with hardness and friability of the said tablets ranges between 10 to 70 kiloponds and less than 2% respectively, the compositions releasing at least 80 percent of the total amount of the ciprofloxacin into a pH 1.2 aqueous dissolution medium within about 1 hour.... Agent: Dr. Reddy's Laboratories, Inc.

20080206330 - Pharmaceutical composition: Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080206333 - Extended release pharmaceutical formulations of s-adenosylmethionine: Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to... Agent: Wilson Sonsini Goodrich & Rosati

20080206332 - Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment: Sustained release oral dosage forms of R-baclofen and methods of treating diseases comprising orally administering such dosage forms are disclosed.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080206331 - Tablet comprising efletirizine and pseudoephedrine: The present invention concerns a tablet comprising two distinct segments. More particularly the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080206334 - Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate: The present invention is directed to a controlled-release pharmaceutical composition providing a sustained delivery of the basic drug Terbutaline sulfate, said composition comprising at least Terbutaline sulfate or a derivative thereof as an active agent, and further comprising an inactive matrix, said matrix comprising a hydrophilic polysaccharide polymer mixture, said... Agent: Schmeiser, Olsen & Watts

20080206335 - Multiparticulate controlled release selective serotonin reuptake inhibitor formulations: A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) formulation for oral administration comprises particles of said SSRI or a pharmaceutically acceptable salt thereof coated with rate-controlling polymer which allows controlled release of said SSRI, over a period of not less than about 12 hours following oral administration. The formulation,... Agent: Fox Rothschild, LLP

20080206336 - Novel composition comprising rosiglitazone and another antidiabetic agent: An oral dosage form comprising an erodable core, which core comprises Compound A or a pharmaceutically acceptable salt or solvate thereof and another antidiabetic agent, the core having a coating with one or more openings, characterised in that the coating is erodable under predetermined pH conditions; a process for preparing... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080206337 - Method of making dosage forms comprising polymeric compositions: A dosage form comprises: (a) at least one active ingredient; (b) a core having an outer surface; and (c) a shell which resides upon at least a portion of the core outer surface, wherein at least a portion of the shell is semipermeable, such that the liquid medium diffuses through... Agent: Philip S. Johnson Johnson & Johnson

20080206338 - Controlled release formulations of an alpha-adrenergic receptor antagonist: The present invention relates to controlled release formulations comprising an alpha-adrenergic receptor antagonist. More particularly, the present invention relates to controlled release matrix formulation comprising alfuzosin hydrochloride and a combination of hydrophilic and hydrophobic polymers prepared by direct compression.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080206339 - Very-pure superporous hydrogels having outstanding swelling properties: The invention relates to methods for preparing superporous hydrogels (SPH) that are very-pure and have desirable swelling properties necessary for commercial use, such as in food and pharmaceutical applications. Such methods include simultaneous use of low and high glass transition monomers to improve impurity and swelling profiles of the SPH,... Agent: Paul D. Yasger Abbott Laboratories

20080206340 - Galactomannans and/or glucomannans for increasing the bioavailability of active substances: The invention relates to a method for increasing the bioavailability of nutrients by using polysaccharides such as galactomannans and similar for introducing active substances, e.g. the human growth hormone HGH and others, into the human or animal metabolism. The aim of the invention is to further develop the production of... Agent: Baker & Daniels LLP 111 E. Wayne Street

20080206342 - Compositions and methods for increasing the bioavailability of pulmonarily administered insulin: A pharmaceutical composition suitable for pulmonary delivery includes insulin and EDTA. The presence of EDTA is effective to increase the relative pulmonary bioavailability of the insulin compared to the relative pulmonary bioavailability exhibited by a composition having the same components but absent the EDTA. The composition is in dry powder... Agent: Nektar Therapeutics

20080206344 - Endocytotic particles: Endocytosis of an active agent into a cell having surface receptors can be enhanced by using particles that have a radius no less than an endocytotic threshold determined based on a surface density of the receptors, a surface density of the moieties and interaction parameters that include at least one... Agent: Conley Rose, P.c. David A. Rose

20080206343 - Hepatocytes and chondrocytes from adherent placental stemcells; and cd34+ ,cd45- placental stem cell-enriched cell populations: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to... Agent: Jones Day

20080206341 - Lipid nanoparticles as vehicles for nucleic acids, process for their preparation and use: The invention relates to solid lipid nanoparticles composed of lipid material and containing, as bioactive molecule, a nucleic acid, preferably an antisense oligonucleotide, preferably modified by chemical methods to achieve a greater resistance to endo- and exo-nucleases, and to the process for preparation of the nanoparticles. In the present invention,... Agent: Collard & Roe, P.c.

20080206345 - Methods for control of soil-dwelling pests and/or soil-borne diseases: A method for the control of soil-dwelling pests and/or soil-borne diseases comprising treating a plant propagation material with an effective amount of the pesticidal composition and/or applying an effective amount of a pesticidal composition to a locus where control is desired, provided that the composition comprises, as active ingredient, one... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080206346 - Preparation of powder agglomerates: The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080206347 - Pharmaceutical formulations comprising active pharmaceutical principles adsorbed on titanium dioxide nanoparticles: The invention provides methods for the adsorption of an active pharmaceutical ingredient on titianium dioxide nanoparticles which can be orally ingested allowing the drug release into the intestine without causing side effects to the upper gastrointestinal region.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080206348 - Cilostazol-containing pharmaceutical composition based on particles of less than 50 micrometers: The present invention relates to cilostazol compositions, process for their preparation, and methods for their administration to treat a condition. In the cilostazol compositions, 90% of the cilostazol particles have a particle size less than about 50 μm.... Agent: Ranbaxy Inc.

20080206350 - Pellets having a gastric juice-resistant active compound matrix: A pellet contains a pharmaceutically active substance embedded in a polymer matrix of one or more water-insoluble polymers; wherein said polymer matrix comprises 10 to 90% by weight of an anionic polymer; with the proviso that the pellet a) releases no more than 10% of said active compound in a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080206349 - Spray dried compositions: The invention provides a method comprising the steps of: (i) providing an emulsion of: a) an aqueous solvent, such as water, b) a carrier material dispersible or soluble in (a), said carrier material being solid at ambient temperature, and preferably being a polymer and inorganic salt or a surfactant, c)... Agent: Unilever Patent Group

20080206351 - Malodor reduction of cosmetic products: Malodor free skin care compositions are described. The skin care compositions comprise an adsorbable solvent and an insoluble particle in an adsorbable solvent-insoluble particle complex. The complex is suitable to adsorb components with malodor to yield a skin care composition free of offensive odors like those generated from the oxidation... Agent: Unilever Patent Group

20080206352 - Extract for preventing or treating thrombotic diseases: An extract for preventing or treating thrombotic disease, particularly, an extract of leech and/or earthworm with molecular weight of not more than 5800 Dalton, and processes for preparation, pharmaceutical compositions and uses thereof. The extract of the present invention has improved significantly safety without any reducing in pharmaceutical activities or... Agent: Zhen Zheng Lu

20080206353 - Formulations and treatments for trichology: a formulation for trichological treatment of a patient including, in a dosage in the range of 3 g to 8 g: phytosterols in the range of 200 mg to 2500 mg; the quantitative equivalent of Polygonum multiflorum root 4:1 in 70% EW in the range of 600 mg to 2600... Agent: Abelman, Frayne & Schwab

20080206354 - Composition for improving hair growth comprising an non-polar solvent-soluble extract of cantharis as an active ingredient: Disclosed herein is a hair growth-stimulating composition containing a non-polar solvent-soluble extract fraction of Cantharis as an active ingredient. The composition shows an excellent hair growth activity with minimal skin irritation compared to conventional ones. It can be used for hair growth in various fields, including medical and non-medical supplies... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080206355 - Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a synthetic cationic polymer: The present invention relates to a composition comprising a composition comprising an effective amount of a particulate zinc material; an effective amount of a surfactant including a surfactant with an anionic functional group; an effective amount of a pyrithione or a polyvalent metal salt of a pyrithione; from about 0.025%... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080206356 - Pharmaceutical compositions for the treatment of neurodegenerative disorders: Pharmaceutical compositions comprising an effective amount of a tungsten (VI) compound, preferably of a tungstate salt, and more preferably of sodium tungstate (Na2WO4), are useful for the prophylactic and/or therapeutical treatment of neurodegenerative disorders in a mammal, including a human, in particular, for the prophylactic and/or therapeutical treatment of Alzheimer's... Agent: Berenbaum, Weinshienk & Eason, P.c

20080206357 - Vif as a traget for hiv inhibition: The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn)... Agent: Venable LLP

20080206358 - Pharmaceutically active compounds, their manufacture, compositions containing them, and their use: A substance for use as a medicament, comprises a solid mixed metal compound of formula (I): MII1−aMIIIaObAn−c.zH2O (I) where MII is at least one bivalent metal: MIII bis at least one trivalent metal; An− is at least one n-valent anion; 2+a=2b+Σcn; and Σcn<0.9a. The substance may be made by heating... Agent: Mayer Brown LLP

20080206359 - Day and night composition and method for treating pseudofolliculitis barbae: An effective formulation for the treatment and prevention of pseudofolliculitis barbae, commonly called razor bumps, and the skin irritation associated with the condition. The treat formulation can be used as the last step in a multi-step shaving system consisting of a shaving gel, aftershave balm and the aforementioned treat. The... Agent: Nikita Wilson

20080206360 - Folate based migraine treatment: Formulations for the prevention and treatment of headaches, particularly migraine headaches, comprise folate in combination with one or more of riboflavin, feverfew, or an extract of feverfew, magnesium in the form of acid salts, magnesium oxide, complexes or chelates and/or other nutritional supplements such as vitamin B6, B12, betaine, and... Agent: Venable LLP

20080206361 - Insecticidal compositions suitable for use in preparation of insecticidal liquid fertilizers: Insecticidal compositions suitable for use in preparation of insecticidal liquid fertilizers comprising a pyrethroid, a hydrated aluminum-magnesium silicate, and at least one dispersant selected from the group consisting of a sucrose ester, a lignosulfonate, an alkylpolyglycoside, a naphthalenesulfonic acid formaldehyde condensate and a phosphate ester are disclosed.... Agent: Patent Administrator Fmc Corporation

20080206362 - Device and method for increasing blood flow and insulin-like growth factor: In order to provide a device and a method for increasing blood flow and an insulin-like growth factor with use of a large amount of carbonic gas nano bubbles, the device of the present invention includes: a bathtub 1; and a nano bubble-producing section 41 for producing carbonic gas nano... Agent: Mark D. Saralino ( Sharp ) Renner, Otto, Boisselle & Sklar, LLP

20080206363 - Skin stabilizer preparation: A method for managing the tolerability of a patient to treatment with a drug that may cause dermatological side effects is provided. An effective amount of a composition which comprises a corticosteroid and sulfur is administered to the skin of such patient.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080206364 - Topical nitric oxide as a treatment of autoimmune diseases: The present invention relates to compositions and methods for treatment of a patient affected with an autoimmune disorder, and in an embodiment, a skin-related autoimmune disorder. The treatment involves the application of gaseous nitric oxide to an affected patient, and in an embodiment, to the skin of an affected patient.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080206366 - Cosmetic composition comprising extract from mallotus japonicus for improving skin wrinkle: The present invention relates to compositions for inhibiting elastase activity, enhancing collagen biosynthesis and improving skin wrinkle, comprising Mallotus japonicus extract as active ingredient. The present compositions exhibit the inhibition effect on elastase activity and promotion effect on collagen biosynthesis at a molecular level, and as a result, excellent efficacy... Agent: Nixon & Vanderhye, Pc

20080206365 - Diterpene compounds having an atisane framework, compositions thereof, and methods of production: Provided are a certain compounds and compositions useful for inhibiting or activating the production of various types of cytokines. Also provided are certain compounds and compositions for preventing or treating various diseases attributable to abnormal cytokine production or compromised immunity.... Agent: Clifford Chance Us LLP

20080206368 - Administration of morinda citrifolia l. based formulations to increase birth rates: The present invention relates to methods and formulations directed to increasing mammalian birth rates comprising the administration of processed Morinda citrifolia based formulations.... Agent: Kirton And Mcconkie

20080206367 - Morinda citrifolia-based formulations and methods for weight management: The present invention relates to formulations and methods for weight management utilizing processed Morinda citrifolia products or extracts. Specifically, the present invention relates to formulations, which may be used for weight loss, regulating gastric motility and regulating plasma levels of cholecystokinin.... Agent: Kirton And Mcconkie

20080206369 - Nutritional supplement preparation with piperine: A nutritional supplement preparation is provided that includes minerals and trace elements such as vitamin D, calcium, magnesium, selenium, copper, zinc and chromium, as well as at least one catalyst and/or active ingredient, preferably in powder form, which increases and/or improves and/or accelerates the absorption of the minerals and/or trace... Agent: Akerman Senterfitt

20080206370 - Method for treating fungoid growth of rhizoctonia, rythium and phytophthora: The invention relates to a method for preventing or treating fungoid growth of the specie Rhizoctonia, Pythium and/or Phytophthora in a plant, in particular for treating chestnut disease, wherein the method comprises making a hole down to the root zone of the plant and putting into this hole a fungicidal... Agent: Foley And Lardner LLP Suite 500

20080206371 - Novel burn treatment composition: The invention is directed to a novel topical burn treatment compositions comprising a silicone containing compound, a Vitamin E compound and a local anesthetic. and their use in treating topical burns.... Agent: Cheryl H Agris Phd

20080206372 - Herbal product to be administered to diabetic people and process to obtain it: Herbal product, for its administration to diabetic people and process to obtain it. The product is made up of the mixture of two plants, one of them belonging to the Myrtaceae family, preferably of the Syzygium species and the other to the leguminosae-caesalpinoideae family and preferably of the Bauhinia variety.... Agent: Dennis G. Lapointe Lapointe Law Group, Pl

20080206373 - Personal care composition comprising botanical extract: Personal care composition comprising at least one extract selected from the group consisting of extracts of Terminalia bellerica, Butea monosperma, Mallotus philippinensis, Anogeissus latifolia, Innula racemosa, Ficus benghalensis, Nerium indicum, Psoralea corylifolia, Acacia catechu, Abies pindrow, Cedrus deodara, Emblica officinalis, Moringa oleifera, Glycyrrhiza glabra, and mixtures thereof, and a dermatologically... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080206374 - Composition of radix codonopsis and radix astragali, a method for preparation thereof and its application: The invention relates to a composition of Radix Codonopsis and Radix Astragali of which the main component is prepared according to a certain weight ratio of Radix Codonopsis and Radix Astragali. The invention also provides a method of preparing the pharmaceutical composition and its applications in the preparation of an... Agent: Dickstein Shapiro LLP

20080206375 - Composition of radix codonopsis and radix astragali, a method for preparation thereof and its application: The invention relates to a composition of Radix Codonopsis and Radix Astragali of which the main component is prepared according to a certain weight ratio of Radix Codonopsis and Radix Astragali. The invention also provides a method of preparing the pharmaceutical composition and its applications in the preparation of an... Agent: Dickstein Shapiro LLP

20080206376 - Methods and compositions for inhibiting angiotensin converting and chymase enzymes: The present invention relates to medicinal products, as well as to health and wellness food products, and particularly to a medicinal product or a health and wellness food product for inhibiting Angiotensin Converting Enzyme and Chymase enzyme pathways.... Agent: Kirton & Mcconkie A Professional Corp.

20080206377 - Topical compositions and methods for alleviating or inhibiting symptoms associated with carpal tunnel syndrome, acid reflux, psoriasis, cartilage nodules, fibromyalgia, and diabetes: The present invention provides a method of alleviating or inhibiting one or more symptoms associated with carpal tunnel syndrome, acid reflux, psoriasis, cartilage nodules, fibromyalgia, diabetes, or hypoglycemia in a mammal. The method comprises the step of contacting the mammal's skin with a composition that includes a fruit-vegetable extract. The... Agent: Wood, Herron & Evans, LLP

20080206378 - Anthelmintic composition: A topical formulation comprising as active ingredients, at least one effective agent derived from Streptomyces avermitilis, i.e. a macrocylic lactone e.g. an avermectin or chemically modified or synthetic derivative thereof, e.g. ivermectin, together with another anthelmintic of the sulphonamide type, e.g. clorsulon, in a carrier that facilitates topical administration and... Agent: Whyte Hirschboeck Dudek S C

20080206380 - Preventing agent against drug-resistant bacterial infection: The present invention is to provide an agent for preventing and treating drug-resistant bacterial infection for livestock/fowls or fish and shellfish, using particular microbial agents as active components, without using synthetic antibacterial substances or antibiotics, and a method for preventing and treating its infection. By using lactic acid bacteria, their... Agent: Morgan & Finnegan, L.l.p.

20080206379 - Production and use of an antioxidant extract from crypthecodinium sp.: The invention relates to an antioxidant extract from Crypthecodinium sp. The invention also relates to a fatty acid composition which comprises at least one unsaturated fatty acid and/or at least one unsaturated fatty acid ester and at least one extract according to the invention and constituents of a biomass different... Agent: Hammer & Associates, P.c.

20080199396 - Radioisotope labelled biological compositions, and their use in accelerator mass spectrometry: wherein B-A* is a biological compound or a derivative thereof formed as the product of reaction of the biological compound to introduce A*, A* is a radioisotopic moiety having MW in the range 10 to 500 comprising an AMS radioisotope * wherein the composition is characterised by a value for... Agent: Jacobson Holman PLLC

20080199397 - Use of a tetrapeptide acsdkp analogue resistant to the angiotensin i conversion enzyme, for measuring glomerular filtration rate in a human or an animal and kit containing same: The invention concerns the use of ACE-resistant N-acetyl-Ser-Asp-Lys-Pro analogues for preparing a reagent or marker adapted to measure a glomerular filtration rate.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080199399 - Interfacing nanostructures to biological cells: Disclosed herein are methods and materials by which nanostructures such as carbon nanotubes, nanorods, etc. are bound to lectins and/or polysaccharides and prepared for administration to cells. Also disclosed are complexes comprising glycosylated nanostructures, which bind selectively to cells expressing glycosylated surface molecules recognized by the lectin. Exemplified is a... Agent: Peters Verny , L.L.P.

20080199398 - Novel peptides that promote lipid efflux: Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080199400 - Otologic nanotechnology: Diagnosing or treating a human ear includes transporting a conjugated nanoparticle or a magnetically responsive nanoparticle into a human's middle or inner ear. Otologic nanophoresis includes electrically, magnetically or electromagnetically driving a nanoparticle through a membrane of the ear, including a tympanic membrane, a round window membrane, an oval window... Agent: Mcafee & Taft Tenth Floor, Two Leadership Square

20080199401 - Method for dissolution of gases with short-lived physical properties in a liquid: The invention relates to a process for dissolving a gas with short-lived physical properties in a liquid, comprising the steps of providing the gas with short-lived physical properties, providing the liquid and bringing the gas with short-lived with short-lived physical properties is fed into the liquid via a semi-permeable membrane... Agent: Hammer & Associates, P.C.

20080199402 - Contrast agents: e

20080199403 - Composition and method for direct visualization of the human appendix: A positive contrast agent composition containing meglumine diatrizoate, sodium diatrizoate, simethicone, famotidine and aspartame in predetermined amounts that is orally administered to a patient for clinical evaluations of appendicitis wherein a positive contrast effect is achieved. Methods of use include orally administering individual doses of the composition approximately 50 minutes... Agent: Robert Plotkin, PC

20080199404 - Contrast agents: p

20080199405 - Compounds and methods for immunotherapy and diagnosis of tuberculosis: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M.... Agent: Townsend And Townsend And Crew, LLP

20080199406 - Verification method: The present invention relates to a verification method of tablets, in particular pharmaceutical tablets. It further relates to an invisible secure marking or information which is a part of such tablet. The invention further relates to tablets suitable for such verification method, to processes for manufacturing such tablets and methods... Agent: Marshall, Gerstein & Borun LLP

20080199407 - Drug detoxification protocol using microdosing: This invention relates to use of an opioid receptor agonist in microdose quantities to reduce or eliminate the withdrawal symptoms associated with discontinuing drug use. The dosage of the agonist is reduced over an extended period of time.... Agent: Mesmer & Deleault, PLLC

20080199408 - Azeotropic fumigant compositions of methyl iodide: Azeotropic and azeotrope-like compositions of methyl iodide and at least one fluorocarbon or hydrofluorocarbon such as 1,1,1,3,3-pentafluoropropane (HFC-245fa). The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a variety of applications,... Agent: Colleen D. Szuch Honeywell International Inc. - Patent Department

20080199409 - Effervescent acidified rehydration preparations: An effervescent acidified rehydration preparation for administration in the drinking water of mammals and poultry includes an amount of a dry generally water soluble acidified electrolyte composition for treatment of dehydration in animals including mammals and poultry by oral administration in the drinking water of animals of interest and an... Agent: Nikolai & Mersereau, P.A.

20080199410 - Pulmonary surfactant formulations and methods for promoting mucus clearance: Methods and compositions to enhance mucus clearance and to treat of pulmonary lung disorders such as cystic fibrosis are disclosed. The methods utilize pulmonary surfactants, alone or combined with hyperosmotic agents, administered to patients in an amount effective to enhance mucus clearance. The compositions comprise a pulmonary surfactant combined with... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080199411 - Cosmetic composition comprising as antiperspirant agent a flocculating water-soluble polymer; process for treating perspiration: t

20080199412 - Anti-staining antibacterial dentifrice: wherein (a) one of A and A′ is hydrogen and the other is a moiety (X)n(R)m, (b) n in individual such moieties is independently 0 or 1, (c) linking groups X if present independently comprise an oxygen, sulfur, nitrogen, phosphorus or silicon atom, (d) where n is 0, m is... Agent: Colgate-palmolive Company

20080199414 - Cosmetic formulation comprising flavonoid derivatives: The invention relates to cosmetic formulations, pharmaceutical preparations, food products and food supplements containing flavonoid derivatives. The flavonoid derivatives act therein, for instance, as UV filter. Some flavonoid derivatives represent novel compounds.... Agent: Millen, White, Zelano & Branigan, P.C.

20080199413 - Novel use of organic compounds: The present invention is directed to the use of a compound selected from the group consisting of β-carotene, lutein, lycopene and β-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including... Agent: Nixon & Vanderhye, PC

20080199415 - Compositions containing a bimodal film former and cross-linked starch: The invention relates to compositions containing (a) at least one bimodal film former; and (b) at least one cross-linked starch as well as to methods of using such compositions and kits containing such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080199416 - Use of anionically and cationically ampholytic copolymers: e

20080199417 - Personal care composition comprising saccharide-siloxane copolymers: A personal care composition comprising at least one saccharide-siloxane copolymer having a saccharide component and an organosiloxane component and linked by a linking group, wherein the saccharide-siloxane copolymer has a specified formula, is provided. The personal care composition is adapted to provide at least one benefit to the at least... Agent: Dinsmore & Shohl LLP

20080199418 - Polysiloxane block copolymers: This invention encompasses novel amphiphilic block copolymers comprising polysiloxane blocks and polycationic blocks. The polycationic blocks are formed from diallyldialkylammonium derivatives. The formed block copolymers are particularly useful for treating or conditioning keratinous substances such as hair or skin.... Agent: Joann Villamizar Ciba Corporation/patent Department

20080199420 - Use of polyisobutenyl succinic anhydride-based block copolymers in cosmetic preparations: The invention relates to novel cosmetic preparations comprising an O/W emulsion, where the O/W emulsion comprises at least one amphiphilic polymer comprising one or more hydrophobic units A and one or more hydrophilic units B, where the hydrophobic units A are formed from polyisobutenes modified with terminal, polar groups, at... Agent: Connolly Bove Lodge & Hutz LLP

20080199419 - Use of water-soluble polymers which are obtained by means of controlled radical polymerisation as an agent for improving the opacity and/or brightness of dry products containing same: The invention relates to agents that are used to improve optical properties such as opacity and/or brightness of dry products based on mineral matter containing said agents. More specifically, the invention relates to a method of producing dry products based on mineral matter, in which the agents used to improve... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080199421 - W/o emulsion: The invention relates to a composition preferably for topical application in the form of a water-in-oil emulsion containing at least one emulsifying silicone elastomer and at least one semi-crystalline polymer. The invention also relates to the use of the composition according to the invention for skincare, and in particular for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080199424 - Mart-1 t cell receptors: T-cell receptors that recognize MART-1 antigen are provided. The TCRs can be used, for example, to treat patients suffering from melanoma.... Agent: Knobbe Martens Olson & Bear LLP

20080199422 - Method for the treatment of myelodysplastic syndromes using 1-oxo-2-(2,6-dioxopiperidin-3-yl-)-4-methylisoindoline: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active... Agent: Jones Day

20080199426 - Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders: Disclosed herein are methods for treating a vascular inflammatory disorder or endothelial cell disorder using inhibitor compounds that inhibit the expression or biological activity of Tie-1, Tie-1 endodomain, thrombin, VEGFR2, VEGFR2 endodomain, EphA2, and any of the cytokines or kinases that are upregulated by activation of Tie-1 or thrombin, as... Agent: Clark & Elbing LLP

20080199423 - Methods of using apo2l receptor agonists and ink cell activators: Methods of enhancing apoptosis or cytolytic activity in mammalian cells using Apo-2L receptor agonists and NK cells, or activating agents thereof, are provided. Apo-2L receptor agonists contemplated for use in the methods include the ligand known as Apo-2 ligand or TRAIL, as well as agonist antibodies directed to one or... Agent: Genentech, Inc.

20080199425 - Sensitization of immune system against haptenized melanoma antigens: The invention is based on the observation that certain phenols, monophenols or benzenediols, can be metabolized into reactive quinones, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1... Agent: Young & Thompson

20080199427 - Novel pyridazine compound and use thereof: e

20080199428 - Treatment of liver diseases in which iron plays a role in pathogenesis: The invention relates to the use of 4-[3,5-Bis-(2-hydroxyphenyl)-[1,2,4]-triazol-1-yl]benzoic acid (hereinafter referred to as “Compound I”) for the manufacture of pharmaceutical compositions for the treatment of liver diseases in humans in which iron plays a role in pathogenesis, including viral diseases, such as chronic hepatitis C, optionally in conjunction with antiviral... Agent: Novartis Corporate Intellectual Property

20080199429 - Cell bandage: The invention provides a method for delivering cells across the surface of a tissue, the method comprising distributing the cells on and/or within a sheet of biomaterial to form a cell bandage and applying the cell bandage to the surface, wherein, after application of the cell bandage to the surface... Agent: Edwards Angell Palmer & Dodge LLP

20080199430 - Methods and kits for qualifying sperm cells: A method of qualifying sperm cells is provided. The method comprising: (a) staining the sperm cells with acridine orange so as to obtain stained sperm cells; and (b) using a fluorescence activated cell sorter (FACS), gating events simultaneously stained with a green fluorescence intensity higher than 100 nm and red... Agent: Martin D. Moynihan Prtsi, Inc.

20080199431 - Self-assembling membranes and related methods thereof: The present invention relates to self-assembling membranes. In particular, the present invention provides self-assembling membranes configured for securing and/or delivering bioactive agents. In some embodiments, the self-assembling membranes are used in the treatment of diseases, and related methods (e.g., diagnostic methods, research methods, drug screening).... Agent: Casimir Jones, S.c.

20080199433 - Complementing cell lines: A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules,... Agent: Trask Britt

20080199434 - Compositions and methods for the treatment of cardiovascular conditions: The present invention provides methods and compositions for treating a cardiovascular condition. In particular, provided is a method comprising administering to a subject an agent that increases the level and/or activity of angiotensin II type 2 receptors. Also provided is a method for evaluating the risk of having or developing... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080199435 - Il-8 like protein: This present invention relates to a novel protein, termed INSP085, herein identified as an IL-8 like protein and to the use of this protein and nucleic acid sequence from the encoding genes in the diagnosis, prevention and treatment of disease.... Agent: Frommer Lawrence & Haug

20080199432 - Role for sry in parkinson's disease: The present invention relates to a method for treating or preventing Parkinson's disease in a patient, the method comprising administering to the patient a therapeutically effective population of neuronal cells transformed with a nucleic acid molecule encoding SRY, wherein the transformed cells express SRY.... Agent: Bozicevic, Field & Francis LLP

20080199443 - Bone morphogenetic variants, compositions and methods of treatment: Human cartilage-derived morphogenetic protein variant polypeptides and isolated nucleic acids are provided. Also provided are vectors, host cells, and recombinant methods for producing human cartilage-derived morphogenetic protein variants polypeptides. Therapeutic methods useful for treating musculoskeletal disorders and joint repair with such variants are also provided.... Agent: Woodcock Washburn LLP

20080199442 - Methods for delivering dna to muscle cells using recombinant adeno-associated virus vectors: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle... Agent: Robins & Pasternak

20080199444 - Composition and method for reducing feces toxins and treating digestive disorders: This invention relates to a method of lowering feces toxin levels and treating digestive disorders (e.g., Irritable Bowel Syndrome or diarrhea) with a composition containing a live beneficial bacterium, a prebiotic, or both. This method includes first identifying a subject in need thereof and then administering to the subject an... Agent: Fish & Richardson PC

20080199445 - Compositions and methods for treatment of microbial infections: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to... Agent: Troutman Sanders LLP

20080199446 - Uronic acid and probiotics: The present invention relates to compositions containing probiotic bacteria and uronic acid oligosaccharides. The compositions can suitably be used as infant nutrition and advantageously reduce the incidence of infection.... Agent: Foley And Lardner LLP Suite 500

20080199436 - Polypeptides having brain-localizing activity and uses thereof: DNAs encoding polypeptides comprising random amino acid sequences were synthesized, and incorporated into a phage library. The phage library produced was used to screen for polypeptides having brain-localizing activity. As a result, several polypeptides having brain-localizing activity were obtained. These polypeptides comprise common sequences, and amino acid motif sequences involved... Agent: Foley And Lardner LLP Suite 500

20080199439 - Iap-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods: The present invention features peptides, peptidomimetics and methods of their use for binding to Inhibitor of Apoptosis Proteins (IAPs) in cells and prevents the IAP's from exerting their apoptosis-suppressing function with caspases in the cell. An IAP binding cargo molecule having a binding portion mimicking the structural and biological features... Agent: Pepper Hamilton LLP

20080199437 - Lrp4/corin dopaminergic neuron progenitor cell markers: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.... Agent: Townsend And Townsend And Crew, LLP

20080199438 - Methods for suppressing tumor proliferation: The present invention provides methods for suppressing tumor proliferation comprising the step of inhibiting the expression of PDGF-A or the binding between PDGF-A homodimers and PDGFRα. Activation of the PDGFRα-p70S6K signal transduction pathway by PDGF-AA is an important factor in tumor angiogenesis and relates to the prognosis of patients suffering... Agent: Clark & Elbing LLP

20080199440 - Tissue repair using allogenic dermal fibroblasts: The present invention provides a method for the repair of subcutaneous or dermal tissue in a subject, comprising in one aspect the injection of a suspension of allogeneic dermal fibroblasts into the subject. By injecting a suspension of allogeneic cells, the invention provides, for example, long-term augmentation of the subadjacent... Agent: Clark & Elbing LLP

20080199441 - Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases: Methods for cell therapy of peripheral vascular disease by local administration of ex-vivo cultured hematopoietic cells are provided.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080199447 - Catalytic domain of adam33 and methods of use thereof: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080199448 - Enzyme composition for improving food digestion: An orally administered composition for improving food absorption and digestion contains therapeutically effective dosages of digestive enzymes and L-glutamine as active ingredients. The digestive enzymes include at least one each of a lipase, a protease, and an amylase, and at least a portion of each of these enzymes is enteric... Agent: Jaeckle Fleischmann & Mugel, LLP

20080199449 - Methods and compositions for use in treating vascular diseases and conditions: The invention includes methods and compositions for use in treating or preventing vascular disease or promoting vascular growth or development. The methods and compositions can be used, for example, in the treatment of diseases associated with ischemia, such as heart attack and stroke.... Agent: Clark & Elbing LLP

20080199450 - Acid ceramidase and cell survival: The present invention relates to methods of promoting the survival of cells by treating the cells with acid ceramidase. A kit for promoting ex vivo cell survival is also disclosed, as is a method of predicting in vitro fertilization outcome of a female subject.... Agent: Nixon Peabody LLP - Patent Group

20080199451 - Composition for the treatment and/or prevention of attacks by biological agents: e

20080199452 - Botulinum toxin compositions and methods: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example.... Agent: Allergan, Inc.

20080199453 - Botulinum toxin compositions and methods: Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, and cholecystitis for example.... Agent: Allergan, Inc.

20080199454 - Caspase inhibitor prodrugs: The present invention relates to compounds of formula I which are prodrugs of caspase inhibitors and pharmaceutically acceptable salts thereof. This invention further relates to the release of caspase inhibitors from these compounds through selective bond cleavage. This invention further relates to pharmaceutical compositions comprising these compounds, which are particularly... Agent: Ropes & Gray LLP

20080199457 - Anti-cd63 antibodies and methods of use thereof: CD63 inhibition of IgE-mediated degranulation in mast cells and in vivo inhibition of allergic processes are described. The invention is drawn to methods of treating allergic conditions and anaphylaxis in a mammal comprising administering an effective amount of an agent that inhibits a function of CD63.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080199456 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group PLLC

20080199455 - Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same: The present invention relates to conformation specific antibodies to TFF and compositions thereof. The present invention also relates to methods of regulation of cellular proliferation and/or survival, particularly methods for the treatment of cancers, tumors and proliferative disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080199458 - Influenza prevention and treatment composition: A composition for influenza treatment includes an immune enhancer and an anti-viral agent... Agent: Evan Law Group LLC

20080199464 - Combination therapy with angiogenesis inhibitors: Disclosed herein are methods of treating tumors using a combination therapy with angiogenesis inhibitors.... Agent: Genentech, Inc.

20080199465 - Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection: A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or... Agent: Novartis Corporate Intellectual Property

20080199463 - Method for treating multiple myeloma: The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.... Agent: Bozicevic, Field & Francis LLP

20080199459 - Mitotic kinesin inhibitors: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080199461 - Ovr 110 antibody compositions and methods of use: The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture... Agent: Licata & Tyrrell P.C.

20080199462 - Preventing airway mucus production by administration of egf-r antagonists: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist... Agent: Bozicevic, Field & Francis LLP

20080199460 - Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080199466 - Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof: Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death,... Agent: Fish & Richardson PC

20080199467 - Immunoglobulin fusion proteins and methods of making: Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20080199468 - Method for diagnosing colorectal cancers: Objective methods for detecting and diagnosing colorectal cancer (CRC) are described herein. In one embodiment, the diagnostic method involves the determining an expression level of C10orf3 that discriminate between CRC and normal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of CRC,... Agent: Townsend And Townsend And Crew, LLP

20080199471 - Optimized cd40 antibodies and methods of using the same: The present invention describes antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20080199469 - Regulation and function of tpl-2: The invention relates to the use of ABIN2 to stabilise TPL-2, and a ternary complex formed between ABIN2, TPL-2 and p105, as well as assays for compounds capable of modulating the interaction between ABIN2 and TPL-2 and/or p105 and use of such compounds in the treatment of inflammatory conditions.... Agent: Edwards Angell Palmer & Dodge LLP

20080199470 - The use of granulin-epithelin precursor (gep) anitbodies for detection and suppression of hepatocellular carcinoma (hcc): This invention provides methods for detecting serum GEP level. This invention further provides methods for determining whether a subject is afflicted with Hepatocellular carcinoma (HCC) by measuring serum GEP level. In another embodiment, this invention provides methods for the suppression of HCC growth and progression both in vitro and in... Agent: Cooper & Dunham, LLP

20080199472 - Use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells: The present invention reates to the use of a polypeptide domain to modulate the tumorigenic and metastatic potential of cancer cells. More specifically, the present invention relates to a domain of a Secretory Leukocyte Protease Inhibitor (SLPI) to modulate tumor invasiveness and/or metastasis. It further relates to compounds, such as... Agent: Trask Britt

20080199477 - Human receptor proteins; related reagents and methods: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080199473 - Novel gene and protein associated with angiogenesis and endothelial cell-specific apoptosis: This invention provides isolated nucleic acid and amino acid sequences encoding VG5Q, a novel angiogenic growth factor protein with pro-angiogenic activity, a forkhead-associated domain, a G-patch domain; characteristic subcellular localization in an in vitro Matrigel model of angiogenesis: towards the cell periphery in early stages of tubulogenesis, between cells in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080199475 - Novel glycosylated peptide target in neoplastic cells: The invention provides polypeptide, nucleic acid and other compositions. Polypeptide, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of hyperproliferative cells or inducing regression of hyperproliferative cells, such as cells of a cellular hyperproliferative disorder, or reducing levels... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080199474 - Porin b (porb) as a therapeutic target for prevention and treatment of infection by chlamydia: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which... Agent: Bozicevic, Field & Francis LLP

20080199476 - Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof: The present invention relates to antibodies, and antigen-binding fragments thereof, specific for urokinase-type plasminogen activator receptor (uPAR) and uses thereof for the treatment or prevention of cancer. In particular, the antibodies of the invention are specific for a particular epitope on uPAR. These antibodies interfere with uPAR signaling. Such antibodies... Agent: Jones Day

20080199478 - Combinations of immunosupressive agents for the treatment or prevention of graft rejections: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute... Agent: Novartis Institutes For Biomedical Research, Inc.

20080199479 - Method of treating a muscle-related condition with modified igf1 polypeptides: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a... Agent: Regeneron Pharmaceuticals, Inc

20080199481 - Compounds: The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis.... Agent: Astrazeneca R&d Boston

20080199480 - Methods for identifying risk of type ii diabetes and treatments thereof: Provided herein are methods for identifying a risk of type II diabetes in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating type II diabetes, and therapeutic and preventative methods applicable to type II diabetes. These embodiments are based upon an analysis... Agent: Grant Anderson LLP C/o Portfolioip

20080199482 - Method for inhibiting the transendothelial migration of cells such as leukocytes or tumor cells by a cd-binding substance and uses thereof: The invention provides a method for inhibiting the transmigration of cells, such as leukocytes or tumor cells, across endothelial cells, by contacting said cells with a CD81 binding agent. Furthermore, the invention provides a method for retarding or inhibiting tissue damage in a subject suffering from an inflammatory disorder, or... Agent: Morrison & Foerster LLP

20080199483 - Long lasting fusion peptide inhibitors of viral infection: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile... Agent: Lowrie, Lando & Anastasi, LLP

20080199485 - Method for enhancing t cell response: Embodiments of the invention disclosed herein relate to methods and compositions for exponentially increasing antigenic stimulation of class I MHC CD8+ T cell responses over that based in the art. Some embodiments relate to an immunogenic composition that enhances an immune response in a subject. In some embodiments, the immunogenic... Agent: Sonnenschein Nath & Rosenthal LLP

20080199484 - Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy: The present invention relates to a method and combination therapy useful in the treatment of cancer. More specifically, the invention relates to the use of COX-2 inhibitors in combination with a therapeutic dendritic cell vaccine for treating cancer. The COX-2 inhibitors of the present invention are believed to inhibit the... Agent: Davis Wright Tremaine LLP/los Angeles

20080199486 - Grp94-based compositions and methods of use thereof: Mini chaperones and methods of use thereof for the treatment of cancer and other disorders are provided. Also provided are tools to facilitate screening therapeutic agents which have selective binding affinity for GRP94.... Agent: Dann, Dorfman, Herrell & Skillman

20080199487 - Glycosylceramide adjuvant for saccharide antigens: The invention provides compositions and kits comprising: (a) a saccharide antigen conjugated to a carrier; and (b) an alpha-glycosylceramide adjuvant. The invention further provides uses of the compositions. It has been found that suppression of anti-saccharide immune responses by alpha-glycosylceramides can be reversed by conjugating the saccharide to a carrier.... Agent: Novartis Vaccines And Diagnostics Inc.

20080199488 - Anti-aids drug: An anti-AIDS agent which comprises, as the active ingredients, one or more components selected from the group consisting of Melastoma villosum Lodd., Dipterocarpus obtusifolius Teijsm ex Miq., Lyophyllum aggregatum, Dictyophora indusiata, pu-erh tea, mentha and stevia. Since the foods having been confirmed as safe in practice are employed, this agent... Agent: Young & Thompson

20080199489 - Skin treatment formulations and method: A series of natural herbal-based ozonated formulations and treatment steps effective in the treatment and prevention of inflammatory skin conditions is described. The formulations provide a novel approach to selection and preparation of medicated formulations where a cocktail approach is appropriate and a logical series of delivery matrices and processes... Agent: Mak Wisnosky

20080199490 - Immunogenic composition: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates wherein the Hib conjugate is present in a lower saccharide dose than the mean saccharide dose of all the at least two further bacterial saccharide conjugates.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080199491 - Sustained release vaccine composition: A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080199492 - Env polypeptide complexes and methods of use: Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein... Agent: Novartis Vaccines And Diagnostics Inc.

20080199493 - Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors: Particular aspects provide for use of the β-herpesvirus Cytomegalovirus (CMV: e.g., RhCMV and HCMV) as a uniquely evolved “vector” for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., HIV, SIV, TB, etc.). Particular aspects provide a method for treatment or prevention of, e.g., HIV,... Agent: Klarquist Sparkman, LLP

20080199494 - Vaccine: A vaccine formulation for the prevention or amelioration of HIV infection in humans is provided. The vaccine comprises an HIV antigen, especially a protein which comprises Nef and/or Tat of HIV, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080199495 - Stimulation of thymus for vaccination development: The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system. In one embodiment the hematopoietic... Agent: Wilmerhale/boston

20080199496 - Genes associated with leishmania parasite virulence: The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerase (PDI).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080199498 - Methods for treating eye disorders: The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis,... Agent: Allergan, Inc.

20080199497 - Pharmaceutical composition comprising botulinum toxin for treating knee joint pain by saphenous nerve entrapment: There is provided a pharmaceutical composition comprising botulinum toxin and a pharmacologically acceptable carrier for treating pain in the knee joint caused by saphenous nerve entrapment. The composition of the present invention is for subcutaneous injection above the medial side of the knee.... Agent: Volpe And Koenig, P.C.

20080199499 - Method for making targeted therapeutic agents: Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is... Agent: Knobbe Martens Olson & Bear LLP

20080199501 - Article/composition combination: The invention relates to a cosmetic article having a water-insoluble substrate and a composition added to or impregnated onto the substrate containing at least one aqueous phase, at least one oily phase and one or more semi-crystalline polymers. This article can constitute in particular a wipe which can be used... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080199500 - Method for the production of resin particles: Resin particles are produced by adding a liquid material having a boiling point of 100° C. or higher to an aqueous dispersion of resin particles to yield a mixture, recovering a wet cake from the mixture by filtration, and drying the wet cake. A water-soluble material is preferably used as... Agent: Birch Stewart Kolasch & Birch

20080199502 - Antimicrobial solution comprising a metallic salt and a surfactant: The present invention concerns solutions having an antimicrobial activity. The solutions described herein comprise particles containing slightly soluble metallic salt and surfactant. In the solutions described herein, the molar ratio between the slightly soluble metallic salt and the surfactant is lower than or equal to about 1. Also described are... Agent: Dann, Dorfman, Herrell & Skillman

20080199503 - Pharmaceutical compositions preparation of peptides, secreted by the snake venom glands, particularly of bothrops jararaca, vasopeptidases inhibitors, evasins, their analogues, derivatives and products associated, thereof, for development of applications: The present invention is characterized by the process of preparation of pharmaceutical compositions for the development of applications of the Evasins and their structural and/or conformational analogues in chronic-degenerative diseases. It is further characterized by the process of preparation of pharmaceutical compositions and related products of the Evasins peptides and... Agent: Birch Stewart Kolasch & Birch

20080199506 - Coating of the entire surface of endoprostheses: The present invention relates to methods for coating the entire surface of lattice-like or mesh-like endoprostheses, wherein the endoprostheses initially are being provided with a thin layer covering the material surface of the endoprosthesis and subsequently, the surface of the entire endoprosthesis is being coated, wherein said coating of the... Agent: J C Patents, Inc.

20080199504 - Dynamers for therapeutic agent delivery applications: Dynamers for use in therapeutic agent delivery systems are disclosed.... Agent: Squire, Sanders & Dempsey LLP

20080199508 - Immobilized bioactive hydrogel matrices as surface coatings: The present invention is directed to a stabilized bioactive hydrogel matrix coating for substrates, such as medical devices. The invention provides a coated substrate comprising a substrate having a surface, and a bioactive hydrogel matrix layer overlying the surface of the medical device, the hydrogel matrix comprising a first high... Agent: Alston & Bird LLP

20080199505 - Local gene therapy with an eluting stent for vascular injury: The present invention relates to a method for preventing or treating stenosis or restenosis in subjects by placement of a polymerized support delivering a recombinant adeno or adeno-associated vector with a mutant Ras nucleic acid encoding a mutant Ras protein which inhibits Ras-mediated phosphorylation, and blocking the Ras signal transduction... Agent: Dla Piper US LLP

20080199509 - Methods and compositions for the disruption of biofilms: The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.... Agent: Sheridan Ross PC

20080199507 - Therapeutic polymeric pouch: An implantable or surface-applied device comprising a porous polymeric pouch containing a therapeutic polymer sealed in the pouch, to provide a localized therapeutic effect at the site of the application. The pores in the polymeric pouch being smaller than the therapeutic polymer, allowing body fluid to enter and exit the... Agent: Borden Ladner Gervais LLP Anne Kinsman

20080199510 - Thermo-mechanically controlled implants and methods of use: An implant comprises a structure that may be implanted into tissue and that has a first material property at normal body temperature. The first material property is variable at elevated temperatures above normal body temperature. The implant also has a plurality of particles dispersed in the structure that are adapted... Agent: Townsend And Townsend And Crew, LLP (client No 021629-000000)

20080199511 - Sustained release compositions containing progesterone receptor modulators: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080199512 - Oral composition for moisturizing skin: Moisture of the skin, skin lipid balance and skin smoothness can be improved by administering an oral composition containing, as active ingredients, proteins and/or protein hydrolysates wherein the total proteins and hydrolysates contain at least 2 wt. % of cysteine residues. Preferably, the hydrolysates have an average molecular weight of... Agent: Morgan & Finnegan, L.L.P.

20080199513 - Systems and methods for preparing autologous fibrin glue: A method of regenerating tissue in a living organism. The method includes the act of contacting an affected area of the living organism with a solid-fibrin web, the solid-fibrin web comprising platelets that release growth factors about one minute after contact to regenerate the tissue in the living organism.... Agent: Michael Best & Friedrich LLP

20080199515 - Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.... Agent: Morrison & Foerster LLP

20080199514 - Functional variant of lymphoid tyrosine phosphatase is associated with autoimmune disorders: The invention is the discovery of a single nucleotide polymorphism in the gene coding for lymphoid tyrosine phosphatase. This SNP leads to a mutation in the lymphoid tyrosine phosphatase protein that prohibits binding with the SH3 domain of Csk, and leads to a subsequent dysregulation of the T-Cell activation cascade.... Agent: Catalyst Law Group, Apc

20080199516 - Encapsulation of lipid-based formulations in enteric polymers: A microcapsule comprising a lipid-based core that is encapsulated in an enteric polymer shell providing enhanced bioavailability of a sparingly water-soluble drug as well as modulated release of the drug, wherein the microcapsule is, in one embodiment, prepared by a centrifugal coextrusion process. The lipid-based core comprises lipidic carriers, either... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080199517 - Composition and a process thereof: The present invention relates to a novel herbal composition for improving exercise physiology factors comprising saponins and sugar derivatives optionally along with pharmaceutically acceptable excipients. It also relates to the process of preparing the composition for improving exercise physiology factors comprising the steps of flaking, defatting, solvent extraction of seeds... Agent: Oliff & Berridge, PLC

20080199518 - Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution: The present invention relates to controlled-release beads comprising diquinoline-substituted piperazine-piperidine compounds, such as 5-fluoro-8-{4-[4-[(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline, or pharmaceutically acceptable salts thereof; to multiple particulate formulations comprising such beads; to methods of preparing such beads; and to methods of treating 5-HT1A-related disorders using such beads and/or multiple particulate formulations.... Agent: Wilmerhale/wyeth

20080199519 - Production of double-or multi-layered microcapsules: The invention relates to a method for production of double- or multi-layered micro-capsules, comprising an inner microcapsule of cross-linked polymers and biological cells and one or more layers of cross-linked polymers without biological cells, which completely enclose(s) the inner microcapsule, whereby, in a first method step, single-layered microcapsules of cross-linked... Agent: Nixon & Vanderhye, PC

20080199520 - S-adenosyl-l-methionine for regulating behavioral disorders in pets: The present invention relates to the use of S-adenosyl-L-methionine or its salts for preparing a composition for the regulation of behavioral problems in pets.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080199521 - Scored pharmaceutical tablets comprising a plurality of secments: Deeply scored pharmaceutical tablets are disclosed, along with pharmaceutical tablets with a score in a segment that adjoins a segment lacking a pharmacologically effective dose of any drug.... Agent: Hedman & Costigan P.C.

20080199522 - Timed-release compression-coated solid composition for oral administration: The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1)... Agent: Townsend And Townsend And Crew, LLP

20080199523 - Particles comprising a releasable dopant therein: A process for making particles comprising a hydrophobic dopant for subsequent release therefrom is disclosed. The process comprises providing an emulsion comprising a hydrophilic phase and a hydrophobic phase dispersed in the hydrophilic phase, and reacting the precursor material to form the particles comprising the dopant therein. The hydrophobic phase... Agent: Foley And Lardner LLP Suite 500

20080199524 - Eyedrops containing particulate agar: It is intended to prepare a composition which contains polysaccharide at a high concentration and yet remains in the state of a liquid having low viscosity to thereby provide drugs, eyedrops, foods, cosmetics, toiletry products having a novel texture or function. The composition in the state of a liquid having... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080199525 - Micronized wood preservative formulations: The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20080199526 - Composition with tight capsules containing a sunscreen agent: The present invention provides a topical composition comprising a first sunscreen agent which is encapsulated and a second sunscreen agent which is different from the first sunscreen agent, characterized in that the first sunscreen agent is encapsulated in microcapsules having an average particle size D(v, 0.5) from 3 μm to... Agent: Nixon & Vanderhye, PC

20080199527 - Enteric coated azithromycin multiparticulates: A pharmaceutical composition is disclosed which comprises multiparticulates wherein said multiparticulates further comprise an azithromycin core and an enteric coating disposed upon said azithromycin core.... Agent: Pfizer Inc.

20080199528 - Colonic delivery of metallo-dependent enzymes: Drug delivery systems for delivering agents capable of reducing the quantity of residual antibiotics reaching the colon following oral or parenteral antibiotic therapy, and for delivering metallo-dependent enzymes, and methods of using the drug delivery systems, are disclosed. The drug delivery systems include pectin beads that encapsulate the active agent... Agent: Intellectual Property / Technology Law

20080199529 - Nanoparticle delivery vehicle: A nanoparticle delivery vehicle, comprising a nanoparticle, an active agent and a nuclear localization signal and methods of modulating gene expression and protein expression employing the nanoparticle delivery vehicle. A representative method includes providing a nanoparticle delivery vehicle comprising a nanoparticle having a diameter of about 30 nm or less,... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080199530 - Abuse-deterrent pharmaceutical compositions of opioids and other drugs: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080199531 - Methods and products for delivering biological molecules to cells using multicomponent nanostructures: This invention is predicated on the present applicants' discovery that nanostructures comprising discrete regions of different composition can be used to deliver to a biological cell a desired combination of molecules in close proximity. Different molecules can be selectively bonded to discrete regions of different composition in sufficiently close physical... Agent: Patent Docket Administrator Lowenstein Sandler PC

20080199532 - Long lasting natriuretic peptide derivatives: This invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative has a NP peptide and a reactive entity coupled to the NP peptide. The reactive entity is able to covalently bond with a functionality on a blood component. In particular, this invention relates to NP derivatives having... Agent: Lowrie, Lando & Anastasi, LLP

20080199533 - Cosmetic and skin care formulation containing pearls, teas and fruits: The present invention relates to a cosmetic and skin care formulation comprising: at least one pearl selected from a group consisting essentially of cultured pearls, Japanese natural pearls, cultured pearls, freshwater pearls, salt water pearls, keshi pearls, mabe pearls and mixtures thereof; at least one tea selected from a group... Agent: Dan M. Delarosa, Esq.

20080199534 - Stability in vitamin and mineral supplements: The invention provides a multivitamin and mineral nutritional supplement composition comprising at least one polyvalent metal and at least one oxidizable vitamin with substantially improved resistance to reactions that lead to darkening and/or spotting and reactions that may reduce the potency of oxidizable vitamins. The composition is a multivitamin and... Agent: Wyeth Patent Law Group

20080199535 - Compositions having a high antiviral and antibacterial efficacy: Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) an antimicrobial agent, (b) a disinfecting alcohol, and (c) (i) an organic acid, (ii) an inorganic salt comprising a cation having a valence of 2, 3, or 4 and... Agent: Marshall, Gerstein & Borun LLP (dial)

20080199536 - Antimicrobial compositions containing colloids of oligodynamic metals: The present invention relates to antimicrobial compositions, methods for the production of these compositions, and use of these compositions with medical devices, such as catheters, and implants. The compositions of the present invention advantageously provide varying release kinetics for the active ions in the compositions due to the different water... Agent: Greenblum & Bernstein, P.L.C

20080199537 - Topical gatifloxacin formulations: Topical ophthalmic solution compositions of gatifloxacin are disclosed. The compositions do not contain disodium edetate or any other metal chelating agent.... Agent: Alcon

20080199538 - Compound to enhance lucid erotic dreams: A compound that contains herbal supplements to increase the frequency and lucidity of a person's erotic or sexual dreams. The compound can be used by anyone wishing to enhance their lucid erotic dreams, or may also be taken by people suffering from jet lag or insomnia. Modes of delivery are... Agent: Greenberg & Lieberman, LLC

20080199539 - Hemostatic compositions and methods of use: Hemostatic compositions comprising a wet layered clay (e.g., wet kaolin) and, optionally, a zeolite, as well as devices and methods of use to promote blood clotting, are provided.... Agent: Bozicevic, Field & Francis LLP

20080199540 - Orally-administrable compositions comprising stable amorphous calcium carbonate: The present invention provides orally-administrable compositions comprising stable amorphous calcium carbonate (ACC). The compositions are preferably prepared as solid dosage forms such as tablets, capsules and powders. The present invention further provides methods for supplementing oral calcium intake in subjects and as well as methods for treating osteoporosis, osteomalacia and... Agent: Nixon & Vanderhye, PC

20080199541 - Liquid chalcogenide compositions and methods of manufacturing and using the same: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.... Agent: Seed Intellectual Property Law Group PLLC

20080199543 - Pharmaceutically active extracts of vitex leucoxylon, a process of extracting the same and a method of treating diabetes and inflammatory diseases therewith: The present invention relates to pharmaceutically active extracts of Vitex leucoxylon exhibiting hypoglycemic and anti-inflammatory properties. This extract is suitable for administrating to animals and humans in treating diabetes, liver disorders and related inflammatory diseases. The extract is found suitable for treating insulin and non-insulin diabetes mellitus.... Agent: Fitch Even Tabin And Flannery

20080199542 - Use of winter savory (satureja montana) or the extracts thereof for the preparation of medicaments for the treatment of the premature ejaculation: The use of Winter savory or its purified extracts rich in rosmarinic acid, the use of rosmarinic acid and the extracts containing it for the preparation of medicaments for the treatment of premature ejaculation.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20080199544 - Compositions and methods for alleviating skin disorders: The disclosure relates to the discovery that fractionated coconut oil is effective for alleviating existing skin disorders when applied topically to the skin of a person afflicted with such a disorder. The disclosure further relates to the discovery that fractionated coconut oil can be used to prevent or inhibit onset... Agent: Duane Morris, LLPIPDepartment

20080199545 - Anti-resorptive and bone building dietary supplements and methods of use: Disclosed herein are dietary supplement compositions and methods for increasing or stimulating bone growth, decreasing or preventing bone resorption, increasing bone strength, improving bone structure, and improving bone architecture comprising a first composition comprising a combination of at least two of: quercetin, Rehmannia sp., Rehmannia sp. root, Siberian ginseng, Sophora... Agent: In Re: 28533 Brinks, Hofer, Gilson & Lione

20080199546 - Anti-resorptive and bone building dietary supplements and methods of use: Disclosed herein are dietary supplement compositions and methods for increasing or stimulating bone growth and, decreasing or preventing bone resorption comprising a first composition comprising a combination of at least two of: quercetin, Rehmannia sp., Rehmannia sp. root, Siberian ginseng, Sophora japonica, licorice, and ipriflavone, wherein the combination of the... Agent: In Re: 28533 Brinks, Hofer, Gilson & Lione

20080199547 - Berry oils and products: The invention includes embodiments of berry oils, cold pressed, and products incorporating the berry oils.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080199548 - Efficient method for producing compositions enriched in total phenols: A product made by a process which results in compositions enriched in total phenols includes purification steps not involving the addition of bisulfite ions. The enriched compositions are characterized as containing monomeric, oligomeric and polymeric phenols, total phenol concentration >12% and exhibiting in vitro COX-2 inhibitory activity enhanced by a... Agent: Hogan & Hartson LLP

20080199549 - Treatment and prevention of inflammation: Disclosed is method of treating or preventing an inflammatory condition, comprising administering to a person in need thereof an amount of a product derived from the plant Pistachia lentiscus var. chia effective to treat or prevent the inflammatory condition. In a preferred aspect the product is a dilution of the... Agent: Sughrue Mion, PLLC

20080199550 - Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof: Disclosed herein a herbal anticancer agent comprising the extract of plant Sphaeranthus indicus or group of compounds obtained from the plant Sphaeranthus indicus. The present invention also discloses a pharmaceutical composition comprising the said agent, methods for preparing the composition and methods of treating all kinds of cancer in mammals... Agent: Darby & Darby P.C.

20080193372 - Efficacy and safety of targeted particulate agents with decoy systems: A decoy inactive carrier composition is administered simultaneously with a targeted composition containing vehicles for delivering a desired agent to a biological target. This simultaneous administration enhances the delivery of the targeted composition to the desired location in a subject.... Agent: Morrison & Foerster LLP

20080193373 - Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders: Described herein are methods for detecting a microorganism or cell in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using microorganisms or cells. Also described are methods which use microorganisms or cells for treating a disease, disorder or condition. Such... Agent: Bell, Boyd & Lloyd LLP

20080193374 - Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy: The present invention relates to cytotoxic agents comprising liposomes wherein the liposomes enclose a solution comprising at least one alpha emitting radionuclide and at least one other therapeutic agent, particularly a chemotherapeutic. The invention also provides methods for the formation of such cytotoxic agents, methods of therapy, especially cancer therapy... Agent: Clark & Elbing LLP

20080193375 - Lung cancer-targeted peptides and applications thereof: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080193376 - Methods of enhanced detection and therapy of inflamed tissues using immune modulation: The present invention relates to methods for the detection and therapy of active atheromatous plaques, and in particular vulnerable plaques, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by the inflammatory cells associated with such plaques.... Agent: Ewards Angell Palmer & Dodge LLP (client: Mgh, Partners)

20080193378 - Radio metal complexes based on bispidine and the derivatives thereof as chelating agents, and use thereof for nuclear medical diagnosis and therapy: The invention relates to specific radioactive metal complexes based on bispidine and the derivatives thereof as chelating agents, the use thereof for nuclear medical diagnosis and therapy, and a method for producing such radioactive metal complexes.... Agent: Renner Otto Boisselle & Sklar, LLP

20080193377 - Radiolabeled nanohybrids targeting solid tumor neovasculature and method of using same: Nanohybrid polymer conjugates that provide a “platform” delivery system is disclosed. The delivery platform provides a multi-focused therapeutic regimen that may be tailored to combat a host of cancers, including advanced-stage, therapy-resistant tumors. The nanohybrids of the instant invention incorporate a configurable polymeric backbone, are multivalent (e.g., may incorporate several... Agent: Foley And Lardner LLP Suite 500

20080193379 - Radioactive diagnostic imaging agent: It is intended to provide a radioactive diagnostic imaging agent comprising a radioactive halogen-labeled compound as an active ingredient, in which the active ingredient is prevented from radiolysis and its stability is improved. This is achieved by adding a biologically-acceptable sugar or sugar alcohol to the radioactive diagnostic imaging agent... Agent: Fitch, Even, Tabin & Flannery

20080193380 - Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy: Provided is a class of radiolabeled androgen receptor targeting agents (ARTA), useful for prostate cancer imaging and in treating or preventing prostate cancer. The agents define a new subclass of radiolabeled compounds, which are selective androgen receptor modulators (SARM), which demonstrate antiandrogenic activity of a nonsteroidal ligand for the androgen... Agent: Pearl Cohen Zedek Latzer, LLP

20080193381 - Heterodimers of glutamic acid: R′ is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment... Agent: Foley And Lardner LLP Suite 500

20080193382 - Methods and compositions for the treatment of sterile inflammation: Described are methods and compositions that inhibit IL-1 signalling for the treatment of acute inflammatory response to cell necrosis, and the attendant collateral tissue damage.... Agent: Fish & Richardson Pc

20080193383 - Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds: A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor... Agent: Moore & Van Allen Pllc

20080193384 - Responsive mri contrast agents: The invention provides MRI contrast agents which provide a high sensitivity and which have an optimised body retention time. These agents enable the mapping of the local pH, temperature, oxygen concentration or other metabolites in a patient's body by the use of Chemical Exchange Saturation Transfer (CEST). Particularly pH and... Agent: Philips Intellectual Property & Standards

20080193385 - Compositions and methods for treating neuropathy: The present invention relates to compositions and methods for alleviating the painful symptoms due to neuropathy. Specifically, the method involves administering to a patient a composition comprising a nitric oxide donor that may be applied topically on the legs or arms to alleviate the negative effects due to neuropathy.... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080193386 - Compositions for treating alopecia or promoting hair growth: The present invention relates to a composition for treating alopecia or promoting hair growth, which contains the blood plasma or serum as an active ingredient. The inventive composition is effective in hair growth, hair growth promotion and hair loss prevention.... Agent: Intellectual Property / Technology Law

20080193387 - Essential oil compositions for killing or repelling ectoparasites and pests and methods for use thereof: Essential-oil compositions comprising Lippia javanica essential oil in combination with one, two, three, four, five, six or more essential oils are provided. The Lippia javanica essential-oil compositions are effective for killing and/or repelling ectoparasites and/or pests, including lice, ticks, mosquitoes, mites, ants and fleas. Methods of using the compositions comprising... Agent: Ricki De Wolff

20080193388 - Mouth wash gum: A new and exciting way of delivering mouth wash to the mouth. The mouth wash is put into gum. The gum is chewed. The mouth wash is then delivered to the mouth through the gum as the gum is chewed. The gum has mouth wash in it. The mouth wash... Agent: Patrick Anthony Tribulato

20080193389 - Use of glycodendrimer reagents for inhibiting adhesion by microorganisms: The present invention is directed to glyodendrimeric proteases, composition with glycodendrimeric proteases and methods for inhibiting adhesion binding in microorganisms by contacting microorganisms with a glycodendrimeric protease or a composition with a glycodendrimeric protease. The invention may be used to treat patients in need of treatment.... Agent: H. Thomas Anderton, Jr. Genencor International, Inc.

20080193390 - Chemical composition and process to obtaining of remover product of carious tissue and application of the product: Chemical composition and process to obtaining of remover product of carious tissue and application of the product formed from a base of Methylparaben solubilized in hot distilled water, in which it's added Papain, Chloramine, Sodium Chloride and Colorant, adding the Sodium Hydroxide little by little and, finally, the composition of... Agent: Pearl Cohen Zedek Latzer, LLP

20080193391 - Alkyl sulfate free and orthophosphate free dentifrice composition comprising fluoride source and a silica dental abrasive: A dentifrice composition is described for combating dental erosion and/or tooth wear comprising a fluoride ion source and a silica dental abrasive, the dentifrice having a Relative Dentine Abrasivity (RDA) value from 20 to 60 and a pH in the range of 6.5 to 7.5 and being free of an... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080193392 - Tooth whitener: Disclosed herein is a tooth whitener using glycerol monooleate. The tooth whitener is a composition that exhibits teeth whitening effects when being applied to teeth. Specifically, the tooth whitener comprises a glycerol monooleate, a polyol, a polymer, a peroxide and a hydrophilic solvent, and has a W/O emulsion phase. The... Agent: The Webb Law Firm, P.c.

20080193396 - A non-rinse off cosmetic composition and a cosmetic product comprising said composition: The present invention relates to a non-rinse-off cosmetic composition that provides to the skin, especially the lip skin, a hydrating and restoring action. More specifically, the invention relates to a non-rinse-off cosmetic composition particularly usable on the skin in the region of the lips, which comprises ricinoleyl monomaleate triglyceride and... Agent: Alston & Bird LLP

20080193394 - Composition for protection and improvement of skin, or reinforcing skin barrier function comprising phosphatidylserine: Disclosed is a composition containing phosphatidylserine as an effective ingredient, and more particularly to a composition containing phosphatidylserine as an effective ingredient for protecting and improving a skin, reinforcing a skin barrier function, suppressing and alleviating an inflammatory response, treating and improving an atopic skin, activating PPAR-a promoting a differentiation... Agent: Merchant & Gould Pc

20080193395 - Cosmetic preparation with vinylpyrrolidone/acrylic acid copolymer: s

20080193393 - Delivery system for topically applied compounds: A delivery system for topically applied compounds is disclosed. The delivery system contains a fatty acid, a phospholipid, and an oil, and is activated by the addition of water. The delivery system is admixed with a topically applied compound and water to provide a composition suitable for application to the... Agent: Marshall, Gerstein & Borun LLP

20080193398 - Derivatives of heptaazaphenalene, methods for obtaining them, and their use as protecting agents against uv radiation: The present invention relates to new heptaazaphenalene derivatives of general Formula (I) and to methods for obtaining them. The physicochemical properties of said compounds allow them to be used as UV radiation absorbents.... Agent: Berenbaum, Weinshienk & Eason, P.c

20080193397 - Use of peroxide decomposers method for the treatment of a material other than the human body: The invention relates to the use of compounds with certain sulfur and optionally nitrogen atom-containing structures as peroxide decomposers in cosmetic and pharmaceutical agents for treating the skin. The invention also relates to cosmetic and pharmaceutical agents comprising compounds having such structures.... Agent: Connolly Bove Lodge & Hutz LLP

20080193399 - Composition comprising argan oil and a plant-based product of the aloe genus, and the cosmetic use thereof: The invention relates to a composition comprising argan oil and an extract of Aloe; the use thereof for producing a cosmetic formulation and the resulting cosmetic formulation.... Agent: Stites & Harbison Pllc

20080193400 - C-glycoside compounds and use thereof for depigmenting the skin: The invention relates to a composition for depigmenting the skin comprising a compound of formula (I): in which: —S represents a monosaccharide or a polysaccharide containing up to 20 sugar units; —the bond S—CH2 being a C-glycoside bond; —X represents a hydrogen atom or a group chosen from —OR1, and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080193402 - Depilatory compositions: The present invention is directed to dual phase and single phase depilatory compositions and methods of using said compositions. More specifically, the present invention is directed to a dual phase composition for the removal of hair comprising a first acidic phase containing a thiol-based depilatory agent and a second alkaline... Agent: Church & Dwight Co., Inc.

20080193401 - Hair treatment composition: The invention provides a hair treatment composition such as a shampoo or conditioner comprising a disaccharide, alkali metal salt and a di-acid or salt thereof. Use of said composition for smoothing and aligning hair, for preventive damage to the hair.... Agent: Unilever Patent Group

20080193404 - Isoalkane mixture, its preparation and use: The present invention relates to an isoalkane mixture, to a method for its preparation and to cosmetic or pharmaceutical compositions which comprise such a mixture.... Agent: Connolly Bove Lodge & Hutz LLP

20080193405 - Use of a water-in-water emulsion polymers in the form of a thickener for cosmetic preparations: The present invention relates to the use of, if appropriate present in the form of an aqueous dispersion, polymers of ethylenically unsaturated anionic monomers for modifying the rheology of aqueous, alcoholic or aqueous/alcoholic cosmetic or dermatological compositions. The polymers are obtainable by free-radical emulsion copolymerization of water-soluble inorganic monomers in... Agent: Connolly Bove Lodge & Hutz LLP

20080193403 - Inducing and maintaining hair color: Hair pigment loss is treated by administration of Substance P or a bioactive analog thereof. The subject may have pigment loss in hair due to any of a variety of reasons, including drug side effects, genetic composition, aging, or nutritional deficit. The treatment can be conveniently administered topically. Maintenance or... Agent: Jones Day

20080193406 - Oral and/or topical compositions comprising prebiotics and fatty acid: Compositions for oral and/or topical administration of a prebiotic and a physiologically active fatty acid, or a salt or ester thereof, are disclosed. The compositions are disclosed as enhancing the body's population of beneficial microorganisms for improving health and well-being.... Agent: Cognis Corporation Patent Department

20080193407 - Ophthalmic compositions containing a synergistic combination of three polymers: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.... Agent: Alcon

20080193408 - Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin: h

20080193409 - Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy: The present invention relates to the use of IL-6 in compositions and methods for therapy or prevention of chemotherapy-induced neuropathy (CIPN). More specifically, the invention relates to the use of a low dose of IL-6 for the treatment and/or prevention CIPN.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080193410 - Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction: The pharmaceutical composition is useful for treating epithelial tumors in a subject and contains at least two antigens and a pharmaceutically acceptable carrier, where each of the antigens induces or is capable of inducing a cutaneous delayed type hypersensitivity (DTH) response in the subject. This composition is particularly useful in... Agent: Hugh Mctavish Mctavish Patent Firm

20080193411 - Anti-viral compounds: Disclosed are compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof of having Formula (I), their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, L1, V, W, T, Z, R, Y1, and p... Agent: Foley & Lardner LLP

20080193413 - Anti-infective agents: s

20080193412 - Method of enhancing the immune response to a vaccine: A method for enhancing the immune response to an antigen or vaccine comprising administering an effective amount of a Th1 stimulatory cytokine, preferably interferon, oromucosally at substantially the same time as administration of an effective amount of an antigen or vaccine.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080193415 - Hsa-free formulations of interferon-beta: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-β) and methods useful in their preparation are provided. The compositions comprise the IFN-β solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-β... Agent: Novartis Corporate Intellectual Property

20080193414 - Use of an immunoglobulin domain-containing cell surface recognition molecule for treating diseases: The invention relates to the use of INSP052 for treatment and/or prevention of infectious disease, properdin-related disease, MBL2-related disease, MASP1-related disease, MASP2-related disease, Antithrombin III-related disease, Complement factor H-related disease and/or Albumin-related disease. Combinations of INSP052 with an interferon, a TNF antagonist or a further anti-infectious or anti-blood clotting agent... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080193417 - Dna encoding insecticidal cry9fa bacillus thuringiensis proteins and recombinant hosts expressing same: The present invention relates to new DNA sequences encoding an insecticidal Cry9Fa protein and insecticidal parts thereof, which are useful to protect plants from insect damage. Also included herein are micro-organisms and plants transformed with a DNA sequence encoding an insecticidal Cry9Fa protein and processes for controlling insects and to... Agent: Buchanan, Ingersoll & Rooney Pc

20080193416 - Herpes virus-based compositions and methods of use: This disclosure features vectors, targeting vectors, modified artificial chromosomes, herpes virus particles in which such chromosomes are packaged, and methods of using the herpes virus particles to identify therapeutic agents and targets for therapeutic intervention.... Agent: Fish & Richardson P.c.

20080193426 - Migration of hematopoietic stem cells and progenitor cells to the liver: The invention relates to transplantation of hematopoietic stem cells (HSC) and/or progenitor cells (HPC) into the liver. More specifically the invention relates to the use of chemokines, preferably SDF-1, for enhancing homing of HSC/HPC to the liver.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080193428 - Composition and method for modulating and maintaining vaginal bacterial flora and vaginal acidity: The present invention relates to the use of benzoic acid and/or its sodium salt in combination with saccharide(s) as active components in the manufacture of a vaginal composition for modulating vaginal flora and vaginal acidity, thereby maintaining the pH value of vaginal secretion within a range from 3.5 to 4.5;... Agent: Ladas & Parry LLP

20080193427 - Means and methods for preventing and/or treating caries: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within... Agent: Connolly Bove Lodge & Hutz, LLP

20080193429 - Probiotic lactic acid bacterium to treat bacterial infections associated with sids: Compositions including a non-pathogenic lactic acid-producing bacteria, such as a Bacillus species, spores or an extracellular product of B. coagulans, formulated for oral administration to the intestinal tract for inhibiting bacterial gastrointestinal infections are described. Methods and systems using the compositions for treating gastrointestinal infections, particularly sudden infant death syndrome... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080193418 - Bacteriophages that infect bacillus bacteria (anthrax): The invention provides bacteriophages that infect Bacillus bacteria, including Bacillus anthracis, and compositions containing the bacteriophages. The invention also provides methods for using the bacteriophages of the invention to detect, prevent and treat infection of an organism by Bacillus bacteria. Methods and materials to decontaminate a surface or an organism... Agent: Intellectual Property Group Fredrikson & Byron, P.a.

20080193419 - Cancer treatment using viruses, fluoropyrimidines and camptothecins: Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma... Agent: Wellstat Management Company. Llc

20080193422 - Method for activating cd4 cell: A method for activating a CD4 T cell includes (1) separating CD4 T cells; and (2) cultivating them in vitro with a culture broth containing cytokines such as GM-CSF, IFN-γ, TNF-α, lectin and IL-4. Also, a therapeutic composition for preventing or treating infectious diseases of bacteria includes CD4 T cells... Agent: The Rafferty Patent Law Firm

20080193420 - Method for the production of a cell composition containing epithelial cells: Disclosed is a method for forming epithelial cells. Said method comprises the steps of aggregating stem cells from differentiated exocrine gland tissue to obtain an organoid body and differentiating at least one portion of the organoid body or a tissue body grown therefrom to obtain epithelial cells. Also disclosed is... Agent: Pearl Cohen Zedek Latzer, LLP

20080193425 - Methods for administering fgf18: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.... Agent: Zymogenetics, Inc. Intellectual Property Department

20080193421 - Multicellular tissue and organ culture systems: The invention relates to methods for producing three-dimensional multicellular tissue and organ culture systems using multicellular mammalian cell aggregates, these systems themselves and their use for various medical purposes, in particular implantations.... Agent: Pearl Cohen Zedek Latzer, LLP

20080193423 - Small organic molecule regulators of cell proliferation: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a compound. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal... Agent: Ropes & Gray LLP

20080193424 - Treatment of tissue defects with a therapeutic composition: Methods for treating a tissue defect include applying therapeutic compositions to the tissue defect. Treatment of a tissue defect, including wound healing can be enhanced by a process including obtaining blood compatible with the subject, fractionating the blood from the subject to produce a blood component, obtaining stromal cells from... Agent: Harness, Dickey & Pierce, P.L.C

20080193430 - Cold storage of modified platelets: A method for storing and using platelets and an associated platelet structure. At least one modified platelet is formed. Each modified platelet includes a platelet and at least one polymerated chemical. Each polymerated chemical includes a polymer covalently bonded directly to the platelet or includes the polymer and a linker... Agent: Schmeiser, Olsen & Watts

20080193431 - Activatable photodynamic therapy agents: The present invention relates to the field of conjugates comprising a substrate which is attached to at least one photoactivatable killing agent and at least one first quencher, and methods for their use. More particularly, the present invention relates to photodynamic therapy agents. The invention further relates to methods for... Agent: Synnestvedt & Lechner, LLP

20080193432 - Compounds having estrogenic activity: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-α-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, γ-tocopherol-9, and analogues thereof. The compounds of the present invention activate ERα and ERβ, and express high estrogenic activity.... Agent: Wpat, Pc Intellectual Property Attorneys

20080193433 - Novel non-toxic composition and use thereof for treatment a degenerative or an immune-related disease: There is provided a non-toxic composition and method of using such for treating a degenerative or an immune-related disease. The non-toxic composition comprises a sprouted grain composition comprising digestive enzymes, a clustered water composition, and a substantially undenatured whey protein composition.... Agent: Ralph A. Dowell Of Dowell & Dowell P.c.

20080193434 - Self-directing and self-assembling nanomedicine into quantized conductance junctions and its process: A self-directed and self-assembled nanomedicine of quantized conductive junction and its preparation process are introduced. In the present disclosure, bio-organic medicine proteins are prepared into a quantized conductive junction with a nanostructure quantum dot and a polymer monolayer on an inorganic silicon surface by seven cooperative modes; and the preparation... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080193435 - Revascularization of ischemic retinal tissue and screening method therefor: The present invention provides a treatment method for promoting beneficial physiological revascularization of ischemic retinal tissue. The method comprises administering to a mammal suffering from a retinal vascular ischemia a therapeutically effective amount of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS), thereby simultaneously inhibiting pathological neovascularization while promoting beneficial physiological... Agent: Olson & Cepuritis, Ltd.

20080193436 - Therapeutic enzyme formulations and uses thereof: Pharmaceutical formulations of glutenase enzymes are provided. The enzymes find particular use in the treatment of a Celiac or dermatitis herpetiformis patient.... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080193438 - Eef2k as modifiers of the pten/akt pathway and methods of use: Human EEF2K genes are identified as modulators of the PTEN/AKT pathway and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT comprising screening for agents that modulate the activity of EEF2K are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080193437 - Immunostimulatory oligonucleotide multimers: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.... Agent: Keown & Zucchero, LLP

20080193439 - Non-anaphylactogenic ige fusion proteins: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders, in particular, the invention provides compositions for the treatment... Agent: Scully Scott Murphy & Presser, Pc

20080193440 - Method for multiple sclerosis treatment and prophylaxis by treatment of leptospira infection: The present invention provides novel therapies and novel prophylactic methods for multiple sclerosis. Also provided are novel diagnostic methods. The invention resides in the finding that multiple sclerosis most likely is caused by chronic infection with a microorganism that cross-reacts immunologically with the spirochete Leptospira interrogans, which normally infects the... Agent: Darby & Darby P.c.

20080193449 - Antibodies specific for dkk-1: Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.... Agent: Merck And Co., Inc

20080193448 - Combinations and methods of using an indolinone compound: The invention provides methods of treating cancer using a compound of formula (1) or a pharmaceutically acceptable salt thereof, particularly a malate salt, in combination with various additional therapeutic agents. The invention also provides therapeutic dosing regimens, using the compound of formula (1) and an additional therapeutic agent.... Agent: Pfizer Inc

20080193446 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20080193447 - Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080193441 - Homogeneous preparations of chimeric protein: Variant forms of chimeric protein molecules comprising a Factor VII moiety and an Fe region of an IgG1 moiety provide improved properties. The variants are more resistant to proteolytic degradation. Thus preparations of the variant forms are more homogeneous and have a longer half-life. The variant forms are used for... Agent: Banner & Witcoff, Ltd.

20080193442 - Inhibition of complement activation: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including... Agent: Nikolaos C. George Jones Day

20080193443 - Methods and compositions for the treatment of polycystic diseases: This invention provides compositions and methods to diagnose and treat polycystic disorders by inhibiting the biological activity of a gene now correlated with appearance of this disorder. By way of illustrative only, the Connective Tissue Growth Factor (CTGF) gene is an example of such a gene. Also provided by this... Agent: Genzyme Corporation Legal Department

20080193444 - Methods of suppressing ltp inhibition: Methods and compositions for suppressing amyloid-mediated inhibition of long-term potentiation (LTP) are provided.... Agent: Townsend And Townsend And Crew, LLP

20080193445 - Novel anti-igf-ir antibodies and uses thereof: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic... Agent: Merck And Co., Inc

20080193450 - Antibodies against candida antigens: This invention relates to domain antibodies. In particular, it relates to domain antibodies (dAbs) that recognize virulence traits of Candida spp. and confer passive protection against candidiasis.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080193451 - Chimeric, human and humanized anti-csap monoclonal antibodies: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.... Agent: Immunomedics, Inc.

20080193452 - Therapeutic compounds derived from spider venom and their method of use: The present invention is directed to new therapeutic compounds isolated from spider venom and methods of using these new compounds. The compounds are sulfated nucleoside derivatives including ribonucleoside mono- and disulfates derived from guanine, adenosine, and cytidine. Some of these compounds are glycosylated or fucosylated bearing one or more sugar... Agent: Burns & Levinson, LLP

20080193453 - Anti tfr antibody: Abstract The invention relates to the monoclonal antibody A24 directed against the transferrin receptor This antibody is in particular useful as an antiproliferative agent.... Agent: Merchant & Gould Pc

20080193454 - Identification of surface-associated antigens for tumor diagnosis and therapy: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates... Agent: Olson & Cepuritis, Ltd.

20080193455 - Novel anti-plgf a antibody: The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.... Agent: Clark & Elbing LLP

20080193456 - Therapy-enhancing glucan: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This... Agent: Law Offices Of Albert Wai-kit Chan, Pllc

20080193458 - 125p5c8: tissue specific protein highly expressed in various cancers: A novel gene (designated 125P5C8) and its encoded protein are described. While 125P5C8 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, bladder, kidney and colon cancers. Consequently, 125P5C8 provides a diagnostic and/or therapeutic target for cancers, and the 125P5C8 gene or fragment... Agent: Agensys C/o Morrison & Foerster LLP

20080193457 - Ra antigenic peptides: The present invention provides novel naturally-processed MHC class II antigenic peptides; which originate from interferon-γ-inducible lysosomal thiol reductase, integrin beta-2, phosphatitylinositol-4,5-bisphosphate 3-kinase, urokinase-type plas-minogen activator, immunoglobulin heavy chain V-III region (VH26), DJ-1 protein, apolipoprotein B-100, 26S proteasome non-AT-Pase regulatory subunit 8, interleukin-1 receptor, fibromodulin, GM-CSF/IL-3/IL-5 receptor, sorting nexin 3, inter-α-trypsin... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080193459 - Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti hsp90 antibodies: The present invention relates to novel compositions and preparations that are effective antifungal agents, and a novel antibody which can be incorporated into the compositions and preparations.... Agent: Jones Day

20080193461 - Use of angiopoietins in tumor therapy: The present invention provides methods for decreasing tumor growth in a subject that rely on detecting an increase in the expression of angiopoietin-1 or a decrease in the expression of angiopoietin-2 in the tumor or in the bloodstream of the subject to detect the normalization window in tumor vasculature.... Agent: Ewards Angell Palmer & Dodge LLP (client: Mgh, Partners)

20080193460 - Chimeric, human and humanized anti-csap monoclonal antibodies: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.... Agent: Immunomedics, Inc.

20080193462 - Methods for inhibiting tumor cell growth: The invention methods using a insulin-like growth factor receptor inhibitor to inhibit tumor cell growth in a subject in need thereof.... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo

20080193463 - Mycoplasma subunit vaccine: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-α-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-α-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals... Agent: Intervet/schering-plough Animal Health Patent Department

20080193467 - Dendritic cell potentiation: A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.... Agent: Fish & Richardson P.c.

20080193464 - Human autism susceptibility gene encoding prkcb1 and uses thereof: The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the PRKCB1 gene of chromosome 16 and... Agent: Occhiuti Rohlicek & Tsao, LLP

20080193465 - Human monoclonal antibodies that specifically bind igf-ii: Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation constant (Kd) of 1 mM or greater. The antibodies inhibit phosphorylation of the insulin-like growth... Agent: Klarquist Sparkman, LLP

20080193466 - Treatment of anemia using tnfalpha inhibitors: Methods for treating anemia in which TNFα activity is detrimental are described.... Agent: Lahive & Cockfield, LLP

20080193468 - Method for stimulating the immune response of newborns: The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist.... Agent: David S. Resnick

20080193469 - Contraceptives based on sp22 and sp22 antibodies: Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.... Agent: Foley Hoag, LLP Patent Group (w/isa)

20080193470 - Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.... Agent: Novartis Vaccines And Diagnostics Inc.

20080193472 - Influenza vaccine formulation: Peptide-based anti-influenza formulations against influenza are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza, particularly avian influenza.... Agent: Borden Ladner Gervais LLP Anne Kinsman

20080193471 - Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080193473 - Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf alpha and a carrier protein: The present invention concerns a novel method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein, the method steps of which are disclosed in the specification.... Agent: Young & Thompson

20080193474 - Immunostimulatory compositions: The present invention provides immunostimulatory compositions. Generally, the immunostimulatory compositions include at least partially purified conjugates that include at least one IRM moiety covalently coupled to an antigenic peptide. In some embodiments, the immunostimulatory composition includes monomeric conjugates. In other embodiments, the immunostimulatory composition includes an aggregate of a conjugate... Agent: 3m Innovative Properties Company

20080193475 - Fermentation process for the production of diphtheria toxin: The present invention relates to a fermentation process comprising a fermentation step of growing a strain of Corynebacterium diphtheria in medium in a fermenter under conditions of agitation sufficient to maintain a homogenous culture and limited aeration such that pO2 within the culture falls to less than 4% for the... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080193476 - Immunogenic composition: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080193477 - Vaccination against dengue virus infection: This invention relates to methods and kits for use in vaccination against dengue virus infection.... Agent: Clark & Elbing LLP

20080193478 - Inactivated poliomyelitis vaccine derived from sabin strain of polio virus: An inactivated Polio Vaccine derived from Sabin strain for safe and effective immunization against Poliomyelitis is provided. A process of preparation for such vaccine and formulations thereof are also provided. Administration of the vaccine of the present invention along with other antigens provides immunization not only against polio infection but... Agent: Ladas & Parry LLP

20080193480 - Infectious bursal disease virus antigenic isolates and vaccines: Antigenic isolates and vaccines for Infectious Bursal Disease Virus include variants of the molecular Group 6 family of IBDV isolates, in particular the 28-1 isolate.... Agent: Wyeth Patent Law Group

20080193479 - Method and compositions for the treatment of hematologic cancers: The present invention relates to oncolytic Picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto... Agent: Dla Piper Us LLP

20080193481 - Synthetic anti-candida albicans oligosaccharide based vaccines: The present invention provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise native O-linked and S-linked oligosaccharides coupled to a protein carrier via a linker, wherein the resultant conjugate elicits a protectively immunogenic response, particularly in vaccines against pathogenic Candida species and more... Agent: Foley & Lardner LLP

20080193482 - Method of cancer screening; method of cancer treatment; and method of auto-immune disease treatment: A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering a needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood... Agent: Michael A. O'neil Michael A. O'neil, P. C.

20080193483 - Recombinant mva viruses expressing clade a/g, clade b, and clade c modified hiv env gag and pol genes: The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.... Agent: Fish & Richardson Pc

20080193484 - Novel methods for producing adenoviral vector preparations with reduced replication-competent adenovirus contamination and novel adenoviral vectors and preparations: This invention provides novel replication-defective adenoviral vectors comprising an adenoviral genome in which the protein IX gene, preferably under the control of its own promoter, is in an inverted orientation relative to the direction of transcription of the native protein IX gene at a location where the protein IX gene... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20080193485 - Food containing a probiotic and an isolated beta-glucan and methods of use thereof: The invention features a food product containing a probiotic and β-glucan isolated from a natural source, methods of treating a disease or disorder by administering the food product, and a package containing separated components of the food product.... Agent: Clark & Elbing LLP

20080193486 - Live, oral vaccine for protection against shigella dysenteriae serotype 1: The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae type 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof;... Agent: Knobbe, Martens, Olson & Bear, LLP

20080193487 - Preparation for vaccination, vaccination method and use of a vaccination preparation: The present invention relates to a pharmaceutical preparation, comprising at least one Toll-like receptor ligand and at least one peptide. The invention also relates to the use of such a pharmaceutical preparation and to a vaccination method.... Agent: Greenblum & Bernstein, P.L.C

20080193488 - Variant polypeptide and screening assay: The invention includes a screening assay for the identification of agents that inhibit the interaction of p53 with p53 inhibitory polypeptides, and p53 inhibitory polypeptide variants that are inactive with respect to the inhibition of p53 activity.... Agent: Marshall, Gerstein & Borun LLP

20080193489 - Personal lubricant compositions that are free of glycerin and parabens: from about 0.1% to about 1.0% by weight polyquaternium; and from about 50% to about 70% by weight water. Also provided are methods of making and using the personal lubricant compositions comprising xylitol. Packaged kits of the compositions and articles of manufacture including the personal lubricant compositions comprising xylitol also... Agent: Bell, Boyd & Lloyd LLP

20080193490 - Use of carbon nanotube for drug delivery: Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and... Agent: Williams, Morgan & Amerson

20080193494 - Antimicrobial solid surface materials containing chitosan-metal complexes: Provided are articles containing a solid surface material with an antimicrobial agent in a thermoset and/or thermoplastic resin matrix, wherein the antimicrobial agent comprises a chitosan-metal complex.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080193492 - Complementary personal lubricant compositions: This invention relates to novel compositions and methods of use by which the compositions of this invention are applied topically to one or more body parts of at least two individuals who bring said body parts into contact with the other individual and, when said body parts come into contact... Agent: Philip S. Johnson Johnson & Johnson

20080193491 - Diaminooxidase-containing pharmaceutical compositions: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.... Agent: Fulbright & Jaworski L.l.p.

20080193493 - Method for treating skin with a pad: Embodiments include treating an area of human skin with a pad on the head of a vibrator.... Agent: Blakely Sokoloff Taylor & Zafman LLP

20080193496 - Antimicrobial and antiviral polymeric master batch, processes for producing polymeric material therefrom and products produced therefrom: A polymeric master batch for preparing an antimicrobal and antifungal and antiviral polymeric material comprising a slurry of thermoplastic resin, an antimicrobal and antifungal and antiviral agent consisting essentially of water insoluble particles of ionic copper oxide, a polymeric wax and an agent for occupying the charge of the ionic... Agent: Townsend And Townsend And Crew, LLP

20080193495 - Disposable hand sanitizer gel dispenser: A disposable hand sanitizer gel dispenser is disclosed. It comprises a base with two straps for releasably adhering to one another for wrapping around a wrist of a user and a plurality of pouches filled with sanitizer gel disposed along the length of the base.... Agent: Vladimir Khiterer Khiterer Law Office

20080193497 - Hydrophilic coating of a water-swellable hydrophilic matrix and an anti-microbial polymer: The present invention relates to a hydrophilic coating of a water-swellable hydrophilic matrix having incorporated therein an anti-microbial polymer, said anti-microbial polymer carrying pendant groups providing the anti-microbial effect, said pendant groups being selected from primary amino groups, secondary amino groups, tertiary amino groups, quaternary ammonium groups, imino groups, and... Agent: Jacobson Holman Pllc

20080193498 - Chemoprotective methods and compositions: Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents. In addition compositions and methods for mitigating or preventing a novel form of... Agent: Scott A. Whitaker, Ph.d., J.d. Senior Intellecual Property Counsel

20080193499 - Angiogenesis inhibitors: Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu

20080193500 - Effect of lmp-1 overexpression on large and small proteoglycans of the disc: A method of treating a disease of an intervertebral disc characterized by an altered amount of at least one proteoglycan, collagen, or heteropolysaccharide in an extracellular matrix of the intervertebral disc are provided. The methods comprise administering to cells of the intervertebral disc having the disease a composition comprising a... Agent: Medtronic Spinal And Biologics

20080193501 - Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to... Agent: Zymogenetics, Inc. Intellectual Property Department

20080193502 - Memantine intravitreal implants: Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is... Agent: Stephen Donovan Allergan, Inc.

20080193503 - Memantine intravitreal implants: Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is... Agent: Stephen Donovan Allergan, Inc.

20080193504 - Method to treat and prevent posterior capsule opacification: The invention provides a method to treat or prevent posterior capsular opacification. The method comprises administering a therapeutically or prophylactically effective amount of a pharmaceutical composition comprising at least one kinase inhibitor. The kinase inhibitor inhibits p38 kinases, ERK kinases, and/or Src family kinases. The invention also provides an ocular... Agent: David S. Resnick

20080193505 - Nutritional compositions for modulating vitamin c bio-availability: The present invention relates to compositions able to modulate Vitamin C bio-availability in individuals. In particular, the present invention pertains to methods for identifying compounds, capable of modulating expression of Vitamin C transporters, the use of said compounds in foods or foodstuffs and the use thereof for the treatment or... Agent: Bell, Boyd & Lloyd LLP

20080193506 - Tooth cleaning kit comprising at least one set of chewing gum pieces: A chewing gum possessing tooth cleaning effects, which chewing gum includes at least gum base and: a) at least one active cosmetic ingredient selected from whitening agents, b) at least one active cosmetic ingredient selected from fresh-breath agents, c) at least one active therapeutic ingredient selected from anti-plaque agents, d)... Agent: Sughrue Mion, Pllc

20080193507 - Wound healing profile: The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions such as wounds. In one aspect, the invention provides wound healing composition characterised by the higher expression levels of phenotypic marker genes such as apolipoprotein D, matrix metalloprotease (2), collagen 3a1 and smooth muscle... Agent: Clark & Elbing LLP

20080193508 - Local anti-infective agent for treatment of nail fungal infections: A topical composition for treating nail fungal infections that utilizes an acidic antifungal agent with a molecular weight no greater than 170 Daltons in a formulation having a pH less than or equal to the pKa of the acidic antifungal agent plus one. Possible antifungal agents include omadine, octanoic acid,... Agent: Paul D. Bianco Fleit Gibbons Gutman Bongini & Bianco Pl

20080193514 - Compostions and methods for iontophoresis delivery of active ingredients through hair follicles: Systems, devices, and methods for delivering one or more active ingredients to deep regions of hair follicles and intradermal tissues in the vicinity of hair follicles. In some embodiments, a composition is provided including an active ingredient carried in a liposome. The liposome includes a cationic lipid and an amphiphilic... Agent: Seed Intellectual Property Law Group Pllc

20080193513 - Dried formulations of nanoparticle-coated capsules: A method of producing a dried formulation for an active substance such as a drug compound is described. The method involves dispersing a discontinuous phase (e.g. an oil-based or lipidic medium) comprising the active substance into a continuous phase (e.g. water) so as to form a two-phase liquid system comprising... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080193512 - Drug carrier and drug carrier kit for inhibiting fibrosis: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative... Agent: Knobbe Martens Olson & Bear LLP

20080193509 - Liposome preparation containing slightly water-soluble camptothecin: The present invention aims at providing a slightly water-soluble camptothecin liposome preparation with an excellent retention in blood for a drug, which can stably hold a slightly water-soluble camptothecin compound for a long period of time, whereby hydrolysis of an α-hydroxylactone ring in blood is suppressed and the slightly water-soluble... Agent: Buchanan, Ingersoll & Rooney Pc

20080193511 - Manufacture of lipid-based nanoparticles using a dual asymmetric centrifuge: The invention relates to a method for producing lipid-based nanoparticles using a dual asymmetrical centrifuge, products produced by means of said method, kits for producing said nanoparticles using a dual asymmetrical centrifuge, and accessories for carrying out the inventive method.... Agent: Needle & Rosenberg, P.c.

20080193515 - Overexpression of wnt ligands and treatment of lytic bone diseases: The present invention is drawn to methods of repairing lytic bone lesions and tumor growth in an individual. In this regard, the present invention discloses use of a Wnt ligand either alone or in combination with anti-Wnt signaling antagonist therapy. The individuals who might benefit from such method may include... Agent: Benjamin Aaron Adler Adler & Associates

20080193516 - Oxygen-carrying blood substitute preparations: An oxygen-carrying blood substitute preparation stable upon storage is provided. The preparation comprises an oxygen-carrying substance capable of reversibly binding and releasing oxygen in vivo and an amount of a physiologically tolerable reducing agent effective for preventing at least partially irreversible oxidation of said oxygen-carrying substance. Preferably the oxygen-carrying substance... Agent: Millen, White, Zelano & Branigan, P.c.

20080193510 - Peptides that target to tumor blood vessels of lung cancer and applications thereof: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080193517 - Polymer conjugates of k-252a and derivatives thereof: The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080193518 - Process for the precipitation and isolation of 6,6-dimethyl-3-aza bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same: The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080193519 - Galenic applications of self-emulsifying mixtures of lipidic excipients: A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps.... Agent: Marsh, Fischmann & Breyfogle LLP

20080193520 - Method for the gentle production of ultrafine particle suspensions and ultrafine particles and the use thereof: The invention describes a multistage process, for producing particles with an average particle size from 50 nm to 1000 nm in a very effective and gentle manner, wherein the solid substance (active substance) is dissolved in a solvent, this liquid containing the solid substance (active substance) in dissolved form is... Agent: Manelli Denison & Selter

20080193521 - Phosphate-binding chitosan and uses thereof: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.... Agent: Choate, Hall & Stewart LLP

20080193522 - Use of polymer mixtures for the production of coated pharmaceutical formulations and pharmaceutical formulation with mixed polymeric coating: The invention relates to the use of mixture of 2 to 60 wt. % of one or more polymers (I) with 40 to 98 wt. % of one or more polymers (II), whereby the polymer (I) is a (meth)acrylate copolymer, containing 90 to 100 wt. % radically polymerised of 40... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080193523 - Composition: The present invention relates to dosage forms for oral administration of therapeutic formulations, adapted to provide immediate and/or sustained-release of therapeutic substances, particularly for oral administration of vitamins. There is provided a dosage form for oral administration of a vitamin, comprising: a liquid phase containing a vitamin, e.g. Vitamin C... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080193524 - Extended release venlafaxine compositions: The invention relates to extended release pharmaceutical compositions of venlafaxine or pharmaceutically acceptable salts. More particularly this invention relates to a pharmaceutical composition having a core comprising venlafaxine and a coating thereupon. The coating utilizes at least one water insoluble polymer and at least one polymer having pH dependent solubility... Agent: Dr. Reddy's Laboratories, Inc.

20080193526 - Pharmaceutical compositions useful in the treatment of pain: There is provided pharmaceutical compositions that are useful for inter alia the treatment of motor fluctuations in patients receiving L-dopa for the treatment of Parkinson's disease comprising a weakly acidic material and a pharmacologically-effective amount of L-dopa, presented in particulate form upon the surfaces of larger carrier particles.... Agent: Morgan Lewis & Bockius LLP

20080193525 - Potassium-magnesium citrate as a surrogate of the dash diet in managing hypertension: The present invention includes compositions and methods for using a single pharmaceutical preparation of KMgCit is a convenient surrogate or to support the DASH diet in lowering blood pressure among patients with essential hypertension. Support is provided by potassium, magnesium and alkali, which overcome the underlying physiological-biochemical disturbances of essential... Agent: Chalker Flores, LLP

20080193529 - Direct compression formulation and process: Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with a glitazone and specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not... Agent: Novartis Corporate Intellectual Property

20080193528 - Dispersible bosertan tablet: The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide.... Agent: Dickstein Shapiro LLP

20080193527 - Pharmaceutical compositions containing quetiapine fumarate: A granule formulation useful for preparation of pharmaceutical compositions. The granule formulation includes a core containing quetiapine or a pharmaceutically acceptable salt thereof as an active ingredient, and a binder agent. The core is coated with a coating layer including a lubricant agent. Solid pharmaceutical compositions containing quetiapine, and their... Agent: Intellectual Property / Technology Law

20080193530 - Use of ranolazine for the treatment of non-coronary microvascular diseases: Disclosed are methods for treating patients suffering from non-coronary microvascular disease comprising administering ranolazine to the patient. In one embodiment, ranolazine is administered as an oral dose.... Agent: Cv Therapeutics, Inc.

20080193531 - Compositions for improving gastrointestinal nutrient and drug absorption: The present invention provides pharmaceutical compositions and methods for improving the absorption of nutrients and/or drugs in the gastrointestinal tract of a subject. Typically, the pharmaceutical compositions comprise a first agent that increases the pH of the stomach, and one or more agents selected from a pH lowering agent, a... Agent: Kv Pharmaceutical Company

20080193532 - Antibiotic product formulation: This invention discloses an antibiotic formulation in an immediate release antibiotic dosage form, comprising an antibiotic, colloidal silicon dioxide, povidone, silicified microcrystalline cellulose, croscarmellose sodium, magnesium stearate and a coating, said formulation having a release profile wherein the Cmax is reached in less than five hours.... Agent: Wyeth Patent Law Group

20080193533 - Sugar-coated agent: A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coated with the sugar... Agent: Sughrue Mion, Pllc

20080193535 - Allergen dosage form: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also... Agent: Darby & Darby P.c.

20080193534 - Process: The present invention relates to a process for the preparation of a stable dispersion of particles, particularly sub-micron particles in an aqueous medium and to a stable dispersion of particles in a liquid medium. The process provided comprises the following steps: 1) combining a) an emulsion comprising a continuous aqueous... Agent: Pepper Hamilton LLP

20080193536 - Cell-laden hydrogels: The present invention provides cell-laden hydrogels and hydrogel assemblies thereof for use in tissue engineering. The invention provides microscale hydrogels (i.e. microgels) having greatest dimensions ranging between about 1 μm and 1000 μm. The present invention provides methods of producing inventive hydrogels and hydrogel assemblies and pharmaceutical compositions thereof.... Agent: Choate, Hall & Stewart LLP

20080193537 - Morphine sulfate formulations: A dosage form comprising a plurality of pellets, the pellets comprising a core element comprising morphine sulfate, a filler and a binder, wherein the morphine sulfate, calculated as the anhydrous form, comprises about 50 wt % to about 85 wt % of the total weight of the core element; and... Agent: Cantor Colburn, LLP

20080193538 - Hyaluronic acid compound, hydrogel thereof and joint treating material: A hyaluronic acid compound which is a reaction product between hyaluronic acid and a phosphatidyl ethanolamine. This compound has biocompatibility and bio-safety, and can be formed into a hydrogel or molded form having a certain shape. Making use of these properties, it is used to treat a knee joint, prevent... Agent: Sughrue Mion, Pllc

20080193539 - Novel stabilized carotenoid compositions: The present invention relates to novel compositions containing finely dispersed carotenoids. The novel compositions of this invention can be used as colorants or additives for food, beverages, animal feeds, cosmetics or drugs. The colorant composition may be a liquid or a solid composition. The solid composition comprises at least one... Agent: Nixon & Vanderhye, Pc

20080193541 - Particulate aqueous system for the preparation of a formulation for the treatment of adipose diseases: Aqueous particulate system comprising at least one water dispersible biopolymer, at least one surfactant, and water for the preparation of a formulation for the treatment of adipose diseases and/or conditions.... Agent: The Firm Of Hueschen And Sage

20080193540 - Solid, oral drug form which has been designed to prevent misuse: The invention relates to the field of solid medicaments that are intended for the oral administration of active ingredients. The aim of the invention is to prevent the improper use of solid, oral medicaments for any user other than the therapeutic use(s) officially approved by the appropriate public health authorities.... Agent: Patton Boggs LLP

20080193543 - Drug delivery formulations for targeted delivery: The size and location of microsphere uptake/delivery are important determinants of the final biodistribution of oral microsphere systems. Formulations, kits, methods of administering the formulations, and using the kits are described herein. The formulations are oral dosage formulations. In one embodiment, the formulations contain microparticles and/or nanoparticles having a homogenous... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080193542 - Injectable deopot formulations and methods for providing sustained release of nanoparticle compositions: Pharmaceutical formulations comprising: a compound selected from the group consisting of ziprasidone, having a maximum average particle size; a carrier; and preferably at least two surface stabilizers are disclosed. The present invention also comprises methods of treating psychosis with such a formulation and processes for making such a formulation.... Agent: Pfizer Inc Steve T. Zelson

20080193544 - Taste masked dosage form containing roflumilast: Taste masked dosage forms for oral administration of roflumilast are described.... Agent: Nath & Associates Pllc

20080193545 - Use of glycerol dipalmitostearate for improving the bioavailability of protein active ingredients in subcutaneous or intramuscular injectable formulations: The invention relates to the use of lipids as formulation agents for increasing the bioavailability of protein active ingredients in subcutaneous or intramuscular injectable formulations.... Agent: Foley And Lardner LLP Suite 500

20080193548 - Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions: The invention relates to a liquid pharmaceutical composition, in the form of a suspension of micronized powder of active substance in an acceptable physiological liquid medium, stabilised over time, for administration via the oral route.... Agent: Law Offices Of Albert Wai-kit Chan, Pllc

20080193547 - Polymeric nanoparticles by ion-ion interactions: The present invention relates to biocompatible and biodegradable, stimuli sensitive, polymeric nanoparticles, which are formed by ion-ion interaction in aqueous media. Synthetic and biological macromolecules with ionizable functional groups are capable of forming nanoparticles whose size and surface properties are sensitive to environmental factors such as pH, temperature and salt... Agent: Thomas A. O'rourke

20080193546 - Solid dose delivery vehicle and methods of making same: The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing... Agent: Morrison & Foerster LLP

20080193549 - Hoki fish liver oil, fractions thereof and therapeutic uses: Oil obtained from the liver of hoki fish is a potent inhibitor of angiogenesis and inflammation, and a modulator of the immune system. Compositions containing hoki liver oil, or fractions thereof, are useful for treating diseases or disorders associated with angiogenesis and inflammation. Certain oil fractions are potent stimulants of... Agent: Seed Intellectual Property Law Group Pllc

20080193550 - Cla-enriched milkfat and uses thereof: The present invention relates to use of c-9, t-11 CLA or a salt, ester or precursor thereof or CLA-enriched milk fat comprising milk fat enriched with c-9, t-11 CLA or a salt, ester or precursor thereof for treating or preventing conditions such as those associated with one or more of... Agent: Knobbe Martens Olson & Bear LLP

20080193551 - Dermatologic use of milk proteins: The invention provides a method for the treatment of acne comprising orally administering to a person suffering from acne an effective amount of a whey protein fraction containing lactoferrin, and preferably containing further specific whey proteins. The lactoferrin is preferably native bovine lactoferrin and the whey protein fraction is administered... Agent: Foley And Lardner LLP Suite 500

20080193552 - Topical medicament for skin injuries and disorders: A topical product for the application to the skin or mucosal surfaces comprises yellow beeswax in an oleaginous base of, e.g., olive oil, sunflower oil, almond oil, cod liver oil, castor oil, along with an excipient vehicle. The product is useful in connection with a variety of conditions and ailments... Agent: Patent Administrator Katten Muchin Rosenman LLP

20080193553 - Chinese patent medicine for treating female mycotic leucorrhea gonorrhea: This invention makes public a kind of Chinese patent medicine for treating female mycotic leucorrhea, gonorrhea. It includes 8-20 weight portions of veronica, 12-30 weight portions of fruit of Chinese azalea, 30-40 weight portions of greenbrier, 15-20 weight portions of fruit of glossy privet. Fleece-flower root, leonurus, “Cao Xian”, calcined... Agent: Eric Chan

20080193554 - Surgical membrane: The invention relates to methods of processing amniotic membrane to generate a substantially ‘growth factor free’ membrane (GFF-membrane), and to methods of processing GFF-membrane to generate membrane enriched with specific and quantified levels of growth factors or other desirable membrane enriching molecules or compounds (E-membrane). The invention extends to GFF-membrane... Agent: Davis Wright Tremaine LLP/los Angeles

20080193555 - Oscillation data recording water: A method of producing oscillation data recording water, comprising preparing minerals containing Fe compound; immersing minerals containing Fe compound in a first purified water to produce water in contact with Fe compound; preparing chemical salt for fixing oscillation data; adding and stirring minerals containing Fe compound and chemical salt in... Agent: Konomi Takeshita Suite 1300

20080193557 - Dental mineralization: A method is provided for mineralizing a dental surface or subsurface including contacting the dental surface with a protein disrupting agent and stabilized amorphous calcium phosphate (ACP) or amorphous calcium fluoride phosphate (ACFP).... Agent: Merchant & Gould Pc

20080193556 - Pka buffered vitamin c composition and method: A pKa buffered vitamin C composition which includes a base alkalizer composition mixed with vitamin C (calcium ascorbate or ascorbic acid). The base alkalizer composition can be approximately 24% to 40% and the ascorbic acid or calcium ascorbate can be approximately 76% to 60% by weight of the vitamin C... Agent: Jeffer, Mangels, Butler & Marmaro, LLP

20080193558 - Stabilized and preserved ketotifen ophth almic compositions: Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein.... Agent: Novartis Corporate Intellectual Property

20080193559 - Pain relief composition comprising paramagnetic silver nanoparticles: The present invention relates to a pain relief composition comprising paramagnetic silver nanoparticles. More specifically, the composition is characterized in that it comprises from 0.03 to 0.05% by weight of paramagnetic silver nanoparticles having specific properties that were not revealed by conventional diamagnetic silver nanoparticles. The pain relief composition according... Agent: The Webb Law Firm, P.c.

20080193560 - Use of arsenic compounds for treatment of pain and inflammation: The present invention relates to the use of arsenic compounds such as sodium meta arsenite (NaAsO2), arsenic trioxide (As2O3), and arsenic hexoxide (As4O6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in... Agent: Mcdermott Will & Emery LLP

20080193561 - Preparation for the prevention and/or treatment of vascular disorders: e

20080193562 - Systems providing at least pesticidal activity: A process reduces the insect, arthropod or pest content in land mass by providing molecular iodine in the land mass in a concentration in aqueous material in the land mass of at least 10 parts per million. The molecular iodine may be added in gaseous or liquid or solid state,... Agent: Mark A. Litman & Associates, P.a. York Business Center

20080193563 - Harnessing wnt signaling to restrict hiv replication: Activation of the Wnt signaling pathway potently restricts HIV replication both in peripheral blood mononuclear cells (PBMCs) and astrocytes. Inducing Wnt signaling, leading to the activation of β-catenin, for example, by the addition of lithium chloride (LiCl) inhibited the replication of a number of HIV isolates in PBMCs. Activating Wnt... Agent: Barnes & Thornburg LLP

20080193564 - Method for preventing or reducing secondary fractures after hip fracture: Use of a bisphosphonate in the preparation of a medicament for the treatment of osteoporosis post hip fracture to prevent or reduce subsequent osteoporotic skeletal fractures in a patient in need of such treatment, and particularly to a patient who has undergone recent repair of the hip fracture and corresponding... Agent: Novartis Corporate Intellectual Property

20080193565 - Dietary supplement containing alkaline electrolyte buffers: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the... Agent: Law Office Of John C. Mcmahon

20080193566 - Use of high dose concentrations of gaseous nitric oxide: The invention relates to a methods and devices of delivering gaseous nitric oxide to a mammal or surface at a concentration ranging from about 1000 ppm to about 50,000 ppm of gaseous nitric oxide. Different conditions which can be treated by high dosage administration of gNO include but are not... Agent: Sidley Austin LLP

20080193569 - Extraction method for producing plant extracts, especially waltheria paniculata extracts containing tiliroside: The present invention relates to a process for the preparation of tiliroside or tiliroside-containing extracts from parts of a plant selected from the Sterculiaceae family, to corresponding extracts, and to the use of the extracts or process products in cosmetics or topical applications.... Agent: Millen, White, Zelano & Branigan, P.c.

20080193567 - Pharmaceutical canscora diffusa-containing composition: The invention relates to a pharmaceutical composition, comprising an active ingredient obtained from a plant of the Canscora species in the gentianaceae family, particularly an active ingredient obtained from a plant of the Canscora diffusa species. The composition according to the invention, comprising a content of Canscora, may be administered... Agent: Frank W. Compagni Morriss O'bryant Compagni

20080193568 - Polyacetylenic compounds: in which R1 is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, or heteroaryl; R2 is H or a monosaccharide residue; R3 is H or C1-C10alkyl; m is 2, 3, or 4; n is 0, 1, 2, or 3; o is 0,... Agent: Fish & Richardson Pc

20080193570 - Composite for the improvement of the smell of the armpit: The present invention relates to a composition comprising ethanol, polyol, salicylic acid, triclosan, allantoin, licorice acid or its di-alkali metallic salt, dl-camphor, houttynia cordata extract, green tea extract, and aloe extract as main ingredients and water and perfume essence as auxiliary ingredients. The present composition has excellent elimination effect of... Agent: Birch Stewart Kolasch & Birch

20080193571 - Extraction of phytosterols from corn fiber using green solvents: The present invention relates to the use of “green” or relatively benign solvents such as ethanol, ethanol/water, isopropyl alcohol, isopropyl alcohol/water, ethyl lactate, acetone, butanol, isoamyl alcohol, or ethyl acetate to extract phytosterols from wet corn fiber. The resulting oil product contains free phytosterols and free fatty acids.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Henry W. Oliver Building

20080193572 - Extracts of ginkgo biloba: Novel extracts from the leaves of Ginkgo biloba, comprising 20 to 30%, by weight, of flavone glycosides; 2.5 to 4.5%, by weight in the aggregate, of ginkgolides A, B, C and J; 2.0 to 4.0%, by weight, of bilobalides; less than 10 ppm of alkyl phenol compounds; and more than... Agent: Cognis Corporation Patent Department

20080193573 - Extracts and methods comprising curcuma species: The present invention relates to extracts of curcuma species plant material using supercritical CO2 extraction methods, methods of treating a subject suffering from suffering from amyloid plaque aggregation or fibril formation associated with, for example, Alzheimer's disease, and methods of inhibiting amyloid plaque aggregation or fibril formation in tissue thereof.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080193574 - Inhibitors of cognitive decline: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and Alzheimer's disease with a derivative of ginger oil are also provided. Also provided is a method of conditioning biological... Agent: Sheldon Mak Rose & Anderson Pc

20080193575 - Compositions containing polysaccharides: The present invention relates to compositions, preferably in the form of a powder and/or granules, which contain as principal components a first component selected from the group consisting of isoflavones, soy products containing at least one isoflavone, and mixtures thereof, together with a polysaccharide as second component. A preferred first... Agent: Stephen M. Haracz Bryan Cave LLP

20080193576 - Antiphlogistic and analgesic composition for topical use in a region of an animal locomotive system: An antiphlogistic and analgesic composition for topical use consists, by weight, of from about 0.01-3% hyaluronic acid, from about 0.5-7% arnica glycolic extract, from about 2-10% of any hydrogel-soluble, non-steroidal anti-inflammatory agent, and 70-95% hydrogel.... Agent: Young & Thompson

20080193577 - Antibacterial substance dm0507 and utilization of the same:

20080187488 - Phage antibodies to radiation-inducible neoantigens: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080187489 - Generator and method for production of technetium-99m: A generator that allows for a non-fission based method of producing and recovering 99mTc from neutron-irradiated molybdenum. This generator system is based on the isolation of 99mTc, as the decay product from a source of 99Mo labelled molybdenum carbonyl Mo(CO)6 through a distillation process. The 99mTc obtained from this distillation... Agent: Gowling, Lafleur Henderson LLP

20080187491 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Wilson Sonsini Goodrich & Rosati

20080187490 - Methods for treating amyotrophic lateral sclerosis: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, immune complexed IgG binding to IgG FγR, and immune complexed IgG binding to mC1q (membrane C1q) or soluble C1q. The... Agent: Fish & Richardson P.C.

20080187494 - Cardiomyocyte production: The present invention provides a process of differentiating stem cells, in particular hES cells, into cardiomyocytes and into neural progenitors by growing the hES cells in the presence of a defined medium that is substantially free of xeno- and serum-components and thus comprises a clinically compliant medium. The defined media... Agent: Scully Scott Murphy & Presser, PC

20080187492 - Drosophila models for diseases affecting learning and memory: Methods of evaluating a compound for the ability to reduce a mental defect in a metazoan are provided, where the mental defect is caused by Fragile X syndrome, a tauopathy, Huntington's disease, neurofibromatosis 1, Parkinson's disease. The methods comprise determining whether the compound reduces a mental effect of the analogous... Agent: Amster, Rothstein & Ebenstein LLP

20080187493 - Peptide-based compounds: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise a targeting vector which binds to receptors associated with integrin receptors.... Agent: Craig Bohlken

20080187496 - Antiperspirant aerosol product with packaging treated against corrosion: An antiperspirant aerosol product comprising an aqueous solution of antiperspirant active emulsified in an oily continuous phase and packaged in a dispensing device comprising an aluminium can body internally lacquered with PAM and a mounting cup lacquered on its bottom side with EPOXY-PHENOLIC-Vinyl lacquer.... Agent: Unilever Patent Group

20080187495 - Reshapable hair styling non-rinse composition comprising (meth) acrylic copolymers: A reshapable hair styling composition comprising, optionally in a cosmetically acceptable vehicle, at least one (meth)acrylic copolymer, wherein the at least one (meth)acrylic copolymer comprises: (a) units derived from at least one monomer chosen from butyl(meth)acrylate monomers, (b) units derived from at least one monomer chosen from hydroxy alkyl(meth)acrylate monomers,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080187498 - Multiphase toothpaste composition: Multiphase toothpaste composition comprising a first phase disposed co-axially within a second phase, each of the phases having a specific gravity of from 1.1 to 1.5 g/ml.... Agent: Unilever Patent Group

20080187497 - Toothpaste: A toothpaste which comprises first and second compositions, the first and second compositions comprising water, humectant and thickener and the second composition disposed coaxially within the first composition, the first composition being a gel and the second composition being opaque, the second composition comprising an opacifier at y % by... Agent: Unilever Patent Group

20080187499 - Tough, long-lasting dental composites: R is an open-chain and/or cyclic alkylene, arylene, or alkylene arylene with 1-10 C, optionally modified by oxygen, sulfur, carboxyl or amino, R1 is an open-chain and/or cyclic alkylene, arylene, or alkylene arylene with 1-10 C, optionally modified by oxygen, sulfur, carboxyl or amino; R′ is an open-chain and/or cyclic... Agent: Gudrun E. Huckett Draudt

20080187500 - Hybrid organic/inorganic chemical hybrid systems, including functionalized calcium phosphate hybrid systems, and a solid-state method for producing the same: A solid-state method of producing functionalized moieties, including placing predetermined amounts of inorganic and inorganic materials and milling media into a vessel rotatably connected to a turntable platform, an amount of an organic material into the vessel, rotating the vessel in a first direction while turning the turntable platform in... Agent: Taft Stettinius & Hollister LLP

20080187501 - Oral composition containing oxidized camellia: Oral composition comprising a Camellia extract of semi-oxidized tissue from a member of the genus Camellia and an enhancing agent.... Agent: Colgate-palmolive Company

20080187502 - Assessment and mitigation of oxidative stress in skin: A method of assessing oxidative stress in a mammal is provided. The method comprises: a) exposing skin cells of said mammal to an oxidizable moiety; b) exposing said skin cells to an external aggression; and c) assessing a reaction product of said oxidizable moiety; wherein prior to said assessing step... Agent: Philip S. Johnson Johnson & Johnson

20080187503 - Antiperspirant/deodorant composition: A composition comprising at least one plant derived oil having a melting point of about −15 to about 38° C. in an amount of about 5% or less by weight; and at least one active chosen from antiperspirant actives and deodorant actives in an amount of about 0.5 to about... Agent: Colgate-palmolive Company

20080187504 - Antiperspirant/deodorant compositions: A composition comprising at least one active chosen from at least one antiperspirant active and at least one deodorant active; a first gellant chosen from at least one fatty alcohol and at least one hydrocarbon of the formula CnH2n+2, wherein n is about 20 to about 100, and the hydrocarbon... Agent: Colgate-palmolive Company

20080187505 - Use of fluorescent polymers for the treatment of human hair: The invention relates to the use of fluorescent polymers for the treatment of human hair, especially for the improvement of hair gloss or the brilliance of human hair or for hair diagnosis as well as corresponding hair treatment agents. The invention also relates to new fluorescent polymers as well as... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080187506 - Hair care composition: Hair care composition comprising from about 0.1% to about 20% of a sulfopropyl(meth)acrylate compound, an alpha methylene lactone, or a mixture thereof, wherein the sulfopropyl(meth)acrylate compound and the alpha methylene lactone each have a molecular weight of less than 500 grams/mole; and a dermatologically acceptable carrier.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080187507 - Shampoo containing a gel network: A shampoo composition comprising: a) from about 5% to about 50% of one or more detersive surfactants, by weight of said shampoo composition; b) a dispersed solid crystalline gel network phase comprising: i) a first component comprising at least about 0.05% of one or more fatty acids by weight of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080187508 - Treatment of golmerular basement membrane disease involving matrix metalloproteinase-12: Methods for treating glomerular basement membrane disease such as Alport syndrome involving matrix metalloproteinase-12 are disclosed. Treatment may be affected, for example, by administering matrix metalloproteinase-12 inhibitors, by administering CCR2 receptor inhibitors, or by administering MCP-1 inhibitors. Matrix metalloproteinase formation is affected by the CCR2 receptor, which is stimulated by... Agent: Mueting, Raasch & Gebhardt, P.A.

20080187510 - Methods for improving drug disposition: The invention provides a method for improving the bioavailability, preferably, oral bioavailability and/or drug disposition, e.g. brain penetration, of an iron chelator, which method comprises co-administering to a mammal, especially a human, in need of such treatment, a combination of an iron chelator and an efflux protein inhibitor.... Agent: Novartis Corporate Intellectual Property

20080187511 - Ointment for cancer treatment: The invention provides an oil-based pharmaceutical composition comprising as an active ingredient phostphatidylserine or a derivative thereof and a pharmaceutically acceptable oil-based carrier, which is formulated for topical or intratumoral administration. Preferably, the composition is an ointment or a cream. The composition can contain additional active agents as well, such... Agent: Leydig Voit & Mayer, Ltd

20080187509 - Pharmaceutical compositions for the treatment of tnf-alpha related disorders: The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0.... Agent: Morgan, Lewis & Bockius, LLP

20080187514 - Methods and compositions for the repair and/or regeneration of damaged myocardium: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of stem cells, such as adult stem cells, optionally with cytokines are disclosed and claimed.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080187512 - Treatment for spinal muscular atrophy: Compositions for treatment of spinal muscular atrophy (SMA) and methods for use thereof to treat SMA and other conditions of SMN-deficiency; novel drug development targets for SMA therapies, and methods of use thereof to screen for candidate therapeutic and diagnostic agents.... Agent: King & Spalding LLP

20080187513 - Treatment of solid cancers: The present invention relates generally to the field of cancer including tumor therapy. More particularly, the present invention relates to the treatment of solid cancers, including solid tumors, and the prevention or reduction of cancer metastasis, by chemoablation of cancer cells by an agent which also stimulates the generation of... Agent: Scully Scott Murphy & Presser, PC

20080187515 - Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines: Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising immunoconjugates that comprise antibodies and anti-idiotype antibodies that mimic an epitope of an antigen that is associated with a tumor or an infectious agent. These immunoconjugates also comprise a peptide... Agent: Immunomedics, Inc.

20080187516 - Acyclic oximyl hepatitis c protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080187517 - Use of serum albumin binding peptides conjugates for the preparation of a medicament: A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080187523 - Anti-angiogenic methods and compositions: Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies.... Agent: Robins & Pasternak

20080187524 - Cellular therapy to heal vascular tissue: The present invention encompasses methods and apparatus for minimizing the risks inherent in endovascular grafting for blood vessel therapy and repair. The invention involves delivering adult stem cells, embryonic stem cells, progenitor cells, fibroblasts, or smooth muscle cells to the diseased blood vessel.... Agent: Medtronic Vascular, Inc.IPLegal Department

20080187522 - Enhancing a population of insulin releasing cells using gfr-a1 agonists: Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-α1/c-Ret receptor complex in insulin secreting cells so as to promote cell... Agent: Fish & Richardson P.C.

20080187520 - Tool for the transfer and production of proteins using the pseudomonas type iii secretion system: o

20080187521 - Use of medulliadrenal chromaffin cells or peptide functional cells: The present invention relates to new use of medulliadrenal chromaffin cells or opioid-peptidergic cells, in particular to their use for treating and/or relieving withdrawal syndrome resulting from drug addiction or drug abuse.... Agent: Ladas & Parry LLP

20080187525 - Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms: Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of Lactobacillus probiotics, bifidogenic enzyme formulations that promote growth of Bifidobacterium probiotics and combination formulations that benefit both types... Agent: Eric P. Mirabel

20080187519 - Chemical dissociation of cell aggregates: The invention provides a novel method of dissociating anchorage independent and dependent cell aggregates. The invention also includes the cells resulting from the methods of the invention and the use of the cells in various applications requiring the generation of a single cell suspension.... Agent: Bereskin And Parr

20080187518 - Production of osteoclasts from adipose tissues: The present invention provides methods for growing and inducing osteoclastic differentiation of adipose tissue derived cells. The present invention further provides methods for administering such adipose tissue derived cells to a subject. The present invention further provides methods for treating diseases, disorders, and conditions associated with aberrant regulation or numbers... Agent: University Of Virginia Patent Foundation

20080187526 - Micronutrient formulations for hearing health: A hearing health micronutrient formulation is provided and the formulation comprises dietary antioxidants and endogenous antioxidants, and the dietary antioxidants are selected from a group consisting essentially of Vitamin A (Palmitate), Vitamin E, Vitamin C (Calcium Ascorbate), Vitamin D3 (Cholecalciferol), B Vitamins, Biotin, Pantothenic Acid (as D-Calcium Pantothenate), Calcium Citrate,... Agent: Dan M. Dela Rosa, Esq.

20080187487 - Methods for producing multilayered particles, fibers and sprays and methods for administering the same: Capsules and particles with at least one encapsulated and/or entrapped agent, such as therapeutic agent, imaging agents, and other constituents may be produced by electrohydrodynamic processes. More particularly, the agent encapsulated in a vehicle, capsule, particle, vector, or carrier may maximize treatment and/or imaging of malignant cancers while minimizing the... Agent: Mcguirewoods, LLP

20080187527 - Novel endometriosis-associated gene: The invention relates to a gene associated with invasive processes, e.g. endometriosis, to a polypeptide coded by said gene, to an antibody directed against the polypeptide, and to the pharmaceutical application of the nucleic acid, the polypeptide and the antibody.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080187528 - Anti-tsg101 antibodies and their uses for treatment of viral infections: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.... Agent: Jagtiani + Guttag

20080187529 - Anti-human vegf receptor flt-1 monoclonal antibody: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a... Agent: Nixon & Vanderhye, PC

20080187534 - Anti-vegf antibodies: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Agent: Genentech, Inc.

20080187531 - Antibodies directed to tumor necrosis factor and uses thereof: Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions... Agent: Knobbe Martens Olson & Bear LLP

20080187532 - Compositions and methods for diagnosing and treating cancer: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080187530 - Novel agents and use thereof: The present invention provides agents for inhibiting the proliferation of cancer cells, wherein the agent inhibits the biological activity of hCAP18/LL-37. In a preferred embodiment, the agent alters the transcription, translation and/or binding properties of hCAP18/LL-37. Preferably, the agent is selected from the group consisting of short interfering RNA (siRNA)... Agent: Birch Stewart Kolasch & Birch

20080187533 - Treatment with anti-erbb2 antibodies: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or... Agent: Genentech, Inc.

20080187535 - Vaccine: The present invention relates to fusion proteins comprising an antigen derived from the so-called tumour rejection antigen PRAME (also known as DAGE) linked to an immunological fusion partner which provides T helper epitopes, such as, for example protein D from Haemophilus influenzae B, fusion partner proteins comprising fragments of protein... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080187536 - Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity: Provided is a simple and safe immunization procedure to reduce cancer incidence and increase longevity by modulating IGF-1 levels in the body. Described are cancer preventive vaccines and methods that elicit circulating antibodies specific to insulin-like growth factor 1 (IGF-1) in the body. Many cancers will be less likely to... Agent: Kevin M. Farrell Pierce Atwood

20080187537 - Method of proliferating plasma cells: The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of... Agent: Fish & Richardson PC

20080187538 - Posh nucleic acids, polypeptides and related methods: The application discloses novel polypeptides and nucleic acids involved in a variety of biological processes, including viral reproduction. Related methods and compositions are also described.... Agent: Ropes & Gray LLP

20080187539 - Method for preventing hiv-1 infection of cd4 cells: This invention provides methods for inhibiting fusion of HIV-1 to CD4− cells which comprise contacting CD4− cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited. This invention also provides methods... Agent: John P. White Cooper & Dunham LLP

20080187540 - Antibodies to ocif-binding molecules: A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein.... Agent: Knobbe Martens Olson & Bear LLP

20080187541 - Helicobacter pylori adhesin binding group antigen: n

20080187542 - Compositions and methods for the treatment of immunologic disorders: Compositions and methods for preventing, reducing or inhibiting immunologic disorders are provided. Suitable compositions include one or more LIGHT-HVEM antagonists. LIGHT-HVEM antagonists include compounds that inhibit, reduce, or block the biological activity or expression of LIGHT and/or HVEM. LIGHT-HVEM antagonists can reduce or inhibit the binding of LIGHT to HVEM,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080187544 - Treating and evaluating inflammatory disorders: Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-α are disclosed, as are other methods.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080187543 - Use of myostatin (gdf-8) antagonists for improving wound healing and preventing fibrotic disease: The present invention relates to a method of improving wound healing in a human or animal patient by inhibiting the activity of myostatin (GDF-8) using one or more myostatin antagonists. The present invention also relates to a method of treating fibrotic diseases or disorders comprising administering a myostatin antagonist.... Agent: Nixon & Vanderhye, PC

20080187545 - Cytomegalovirus surface protein complex for use in vaccines and as a drug target: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080187546 - Method for replicating influenza virus in culture: The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce a tissue-culture adapted viral isolate. The invention also includes vaccines produced from the isolate.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080187547 - Irta-5 antibodies and their uses: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-5 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions... Agent: Baker Botts L.L.P.

20080187550 - Immunomodulatory peptides derived from heat shock proteins and uses thereof: A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the inflammation-related symptoms of an immune-mediated disease, such as arthritis, can be achieved by modulation of the underlying immune response itself, rather than by... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20080187553 - Immunstimulating lipid formulation: A pharmaceutical formulation for parenteral or mucosal administration of antigens and/or vaccines to humans and animals, comprising monglyceride preparations having at least 80% monoglyceride content and where the acyl group contains from 6 to 24 carbon atoms, together with fatty acids where the number of carbon atoms may be varied... Agent: Bacon & Thomas, PLLC

20080187552 - Novel vaccine composition and use of surfactants as adjuvants of immunity: p

20080187548 - Ny-eso-1 peptides which bind to class ii molecules and uses thereof: The invention relates to peptides which consist of amino acid sequences found in the NY-ESO-1 molecule, which bind to MHC-Class II molecules. These can be used alone, or in combination with other peptides.... Agent: Fulbright & Jaworski, LLP

20080187549 - Polyantigenic-based (multiple antigens) modi or set of methods for developing infertility vaccines: Because humans and many domesticated animals (cats, dogs, cattle, sheep, birds, etc.) are such out-bred species, in that they may possess a broad variety of gamete-based antigens, individual responsiveness to an immunologic vaccine which uses a single or highly limited number (one or two) of isolated/identified antigens, is apt to... Agent: William A. Morey

20080187551 - Polypeptides: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.... Agent: Fitzpatrick Cella Harper & Scinto

20080187554 - Process for producing stable hiv th-ctl peptides: A process for producing a stable formulation of hydrophobic HIV Th/CTL peptides first requires the preparation of a formulation buffer containing 12.5 mM succinic acid and 3% mannitol, and adjusting the pH of the formulation buffer to 1.7 to 2.1. The hydrophobic peptides are then dissolved in the formulation buffer,... Agent: Wyeth Patent Law Group

20080187555 - New vaccine formulations: p

20080187556 - Medicine for treating tumor and use therefor in preparation of the medicaments for treating tumor: Disclosed herein is a medicine comprising an active component of Rabies Vaccine for Human Use and methods of using thereof to treat tumors and HPV infections. The compositions and methods did not result in any observable side-effects in the experiments disclosed herein and were observed to adjust body function and... Agent: Smith, Gambrell & Russell

20080187557 - Vaccine against pandemic strains of influenza viruses: The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering... Agent: Klarquist Sparkman, LLP

20080187558 - Allergen dosage form: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also... Agent: Darby & Darby P.C.

20080187559 - Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response: The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080187560 - Antimicrobial rubber formulations and molded article: This disclosure relates generally to molded rubber articles such as the type used in water contact applications. More particularly, this disclosure is directed to molded rubber articles containing antimicrobial agents that control biofilm growth on the surface of the molded article. The molded rubber article is comprised of curable rubber... Agent: Brenda D. Wentz Legal Department, M-495

20080187561 - Enteric coated didanosine compositions having a subcoat: The present invention relates to enteric coated didanosine compositions having a subcoat comprising hydroxypropyl methylcellulose, and process for preparation thereof. The enteric coating ranges from 19-25% w/w of the composition. The compositions are stable and have acceptable acid resistance and release profile.... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20080187562 - Antiperspirant/deodorant compositions: A composition comprising at least one active chosen from at least one antiperspirant active and at least one deodorant active; a first gellant chosen from at least one fatty alcohol and at least one hydrocarbon of the formula CnH2n+2, wherein n is about 20 to about 100, and the hydrocarbon... Agent: Colgate-palmolive Company

20080187563 - Oxygen delivery compositon: A composition is disclosed comprising a particle comprising the produce produced by the contacting of a silicate and a titanium containing compound, and at least one of a peroxide containing polymer, a cosmetically acceptable carrier, or a combination thereof. Also disclosed is a method for preparing a composition, comprising a)... Agent: Needle & Rosenberg, P.C.

20080187565 - Composite material including a thermoplastic polymer, a pest food material and a pesticide: Composite materials that are palatable to a wood-destroying pest species and also pesticidal to the pest species can be used in pest control devices and can be used as wood substitutes for structural components, which are resistant to destruction by wood-destroying pests. The composite materials include a thermoplastic polymer, a... Agent: Dow Agrosciences, LLC

20080187564 - Pest-control member: A pest-control member used to prevent equipment from pest damage by being attached to a target that becomes a migration path for pests entering the equipment, the pest-control member being configured so that it is entirely made of resin, its diameter is located perpendicular to the target when attached to... Agent: Carr & Ferrell LLP

20080187566 - Sustained release delivery systems for turf, pasture, and home applications: A method to control on a sustained basis insect pests wherein the insect pests are exposed to repellent chemicals lodged in a high tortuosity microporous polymeric material.... Agent: Mueller And Smith, Lpa Mueller-smith Building

20080187569 - Dissolution of arterial plaque: Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 μM are achieved; in some embodiments levels ranging from... Agent: Mcdermott Will & Emery LLP

20080187567 - N-substituted monomers and polymers: Biocompatible, bioresorbable polymers comprising a plurality of monomeric repeating units containing an amide group, wherein said amide groups are N-substituted and the N-substituent and degree of N-substitution are effective to lower the melt viscosity, the solution viscosity, or both, compared to the same polymer without N-substitution.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080187568 - Polymerization with precipitation of proteins for elution in physiological solution: Methods and compositions for polymerizing materials with the process of making the material causing precipitation of an agent that is subsequently released by the material. In some aspects, controlled delivery of bioactive substances from biodegradable hydrogels is disclosed. In certain embodiments, biodegradable hydrogels formed in situ comprise entrapped precipitated proteins... Agent: Dardi & Associates, PLLC

20080187570 - Dna-based coatings for implants: The invention relates to implants having a coating comprising DNA to improve the tissue-response at the site of implantation.... Agent: Foley And Lardner LLP Suite 500

20080187571 - Bioactive bone graft substitute: The invention relates to biocompatible bone graft materials for repairing bone defects and the application of such bone graft materials.... Agent: Woodcock Washburn LLP

20080187572 - Matrix metalloproteinase inhibitors of tgfb-induced subcapsular cataract formation: The present invention provides novel methods and compositions for the treatment and/or prevention of cataracts. A composition that inhibits destabilization of E-cadherin is administered. Preferably the composition comprises a matrix metalloproteinase inhibitor.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080187573 - Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase b inhibitor component: A fast dispersing solid pharmaceutical composition having a monoamine oxidase B inhibitor as the only active ingredient is disclosed for the treatment of Parkinson's disease. The composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membranes, such that at least 5% of the active ingredient... Agent: Stroock & Stroock & Lavan LLP

20080187574 - Mycellated grain and other myceliated agricultural materials to be used as animal food supplement: Animal feedstuff having beneficial properties is obtained by adding to a substrate one or more fungal species of the kind that excretes substances into said substrate during its growth which are beneficial to the health, growth or weight gain of an animal, or animals to which the feedstuff is intended... Agent: Gabor L. Szekeres

20080187577 - Immunogenic compositions comprising progastrin and uses thereof: The present invention is drawn to immunotherapeutic methods to treat tumors/cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in... Agent: Benjamin Aaron Adler Adler & Associates

20080187576 - Methods for treating articular disease or dysfunction using self-complimentary adeno-associated viral vectors: Disclosed are methods and compositions for treating articular diseases such as osteoarthritis and rheumatoid arthritis, or articular dysfunction in mammals. Also disclosed are self-complimentary AAV vectors useful in gene therapy and delivery of therapeutic constructs to mammalian cells, and in particular, articular joints, cartilage, ligaments, tendons, and surrounding tissues.... Agent: Haynes And Boone, LLP

20080187578 - Platinum aggregates and process for producing the same: One aspect of the disclosure relates to a new form of lipid-complexed active platinum compound, which allows for high concentrations of platinum compound in the composition. For example, the concentration of cisplatin in the composition is higher at room temperature, e.g., about greater than 1.2 mg/mL, compared to 1 mg/mL... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080187575 - Pyrimidine derivatives: The present invention relates to pyrimidine derivatives, methods for their synthesis, and the use of said pyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases,... Agent: Leon R. Yankwich Yankwich & Associtaes

20080187579 - Extended-release dosage form: Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially surrounding the inner core bead, and an outer coating substantially surrounding the intermediate coating comprising a pH independent polymer. Also provided is a pharmaceutical formulation comprising two... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080187580 - Therapeutic nucleosides: The use of a 1,3-oxathiolane nucleoside analogue and pharmaceutically acceptable derivatives thereof for the treatment of hepatitis B virus infections is disclosed. Pharmaceutical formulations are also provided.... Agent: King & Spalding LLP

20080187581 - Delivery system for mulitple drugs: A solid pharmaceutical dosage form comprises a substrate containing an active agent and a solid composition deposited onto areas of a surface of the substrate and containing an active agent.... Agent: Dr. Reddy's Laboratories, Inc.

20080187582 - Pharmaceutical composition comprising an indolylmaleimide derivative: The application relates to solid pharmaceutical compositions suitable for oral administration comprising a water sensitive drug, preferably an indolylmaleimide derivative, process for their production and use of the pharmaceutical compositions.... Agent: Novartis Corporate Intellectual Property

20080187584 - Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof: Provided are formulations of a stable paroxetine hydrochloride tablet comprising paroxetine hydrochloride, povidone or copovidone as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method. Preferably, the paroxetine hydrochloride is paroxetine hydrochloride hemihydrate.... Agent: Kenyon & Kenyon LLP

20080187583 - Tablet containing hydrogenated phospholipids: The present invention provides a process for preparing a tablet containing hydrogenated phospholipids and the tablet obtainable by such process.... Agent: Needle & Rosenberg, P.C.

20080187585 - Prolonged-release compositions comprising torasemide and a matrix-forming polymer: Prolonged-release diuretic compositions containing torasemide as active ingredient The compositions of the invention are useful to be able to avoid the troublesome unitary urgencies caused by conventional immediate-release compositions.... Agent: Birch Stewart Kolasch & Birch

20080187587 - Controlled release formulations containing an active ingredient, preferably melatonin and the method of preparation: o

20080187586 - Pharmaceutical compositions for glucocorticoid replacement therapy: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereof in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period... Agent: Thorpe North & Western, LLP.

20080187588 - Formulations with controlled release of active ingredient: The present invention relates to novel pharmaceutical dosage forms with controlled release of active ingredient which comprise the PDE 5 inhibitor vardenafil and/or pharmaceutically acceptable salts, hydrates, solvates and/or polymorphic forms thereof as active ingredient, and to the production thereof. The invention further relates to the use of these novel... Agent: Bayer Health Care LLC

20080187589 - Multi-modal delivery via transmucosal and gastro-intestinal absorption of antihistamines and symptom relief: A multi-modal absorption, medicine-delivery lozenge is provided. The lozenge includes a lozenge base for oral administration into a user's mouth, a medicinal active ingredient including an antihistamine convertible between ionized and non-ionized states, and a buffer present in an effective amount for establishing a pH in the individual's mouth which... Agent: Berenato, White & Stavish, LLC

20080187590 - Oral dosage form: An oral dosage form of entacapone and methods for the preparation thereof are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080187591 - Rapidly acting dry sealant and methods for use and manufacture: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit... Agent: Baxter Healthcare Corporation

20080187592 - Cosmetic composition comprising a tensioning agent and a hydroxyalkyl urea: The present invention relates to a cosmetic composition, in particular an anti-wrinkle composition, comprising, in a physiologically acceptable medium suitable for topical application to facial skin: (a) at least one tensioning agent chosen from: plant proteins and hydrolysates thereof, mixed silicates, colloidal particles of inorganic filler and synthetic polymers; and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080187593 - Methods for treating diseases of altered ige regulation: Techniques for treating one or more diseases of altered IgE regulation in a patient are provided. For example, a technique for treating one or more diseases of altered IgE regulation in a patient includes the step of administering a therapeutically effective amount of one or more sophorolipids to the patient... Agent: Ryan, Mason & Lewis, LLP

20080187596 - Benefit agent containing delivery particle: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080187594 - Dosage form with improved release of cefuroximaxetil: The invention relates to a pharmaceutical composition comprising cefuroximaxetil and at least one carrageenan selected from the group consisting of κ-carrageenan, λ-carrageenan and τ-carrageenan. The invention furthermore relates to pellets, to a multiparticulate, pharmaceutical dosage form and to a novel crystalline modification of cefuroximaxetil.... Agent: Crowell & Moring LLP Intellectual Property Group

20080187595 - Method for carrying therapeutic substances into cells: The present invention relates to compositions containing nanoparticles and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and... Agent: J C Patents, Inc.

20080187597 - Sustained release preparation comprising a foamed capillary tube: Provided is a sustained release preparation capable of uniformly releasing therefrom a volatile chemical for a long period of time even if the amount of a liquid chemical remaining in a tubular container of the sustained release preparation becomes small. Also provided is a container for sustained release preparation, the... Agent: Roberts Mlotkowski Safran & Cole, P.C.

20080187598 - Baby diaper cream for diaper itch and diaper red sore: A baby diaper cream for diaper itch and diaper red sore includes a predetermined amount of herbal medicine, comprising a predetermined amount of Forsythia and a predetermined amount of Honeysuckle, a predetermined amount of catalyst comprising vitamin E, and a predetermined amount of a binding agent.... Agent: David And Raymond Patent Firm

20080187599 - Method and apparatus for pressure sodding a biological vascular conduit: The present invention is directed to a method for lining a biological vascular conduit with cells. The method utilizes a suitable biologic tube conduit with luminal characteristics that simulate exposed basement membrane to allow for cell attachment. The biologic conduit is secured within a seeding chamber. Cells are introduced into... Agent: David S. Resnick

20080187600 - Method of disinfecting food and food preparation areas: Hydrogen peroxide is stabilized by the addition of tri-potassium phosphate at a pH above 9.5. This enhanced product is environmentally friendly and can be used in a variety of odor and disinfection applications without hazard to people, plants and things. Such applications include food and food preparation areas.... Agent: Benasutti, P.A.

20080187601 - Polyoxometalate materials, metal-containing materials, and methods of use thereof: The invention relates to a polyoxometalate topical composition for removing a contaminant from an environment, comprising a topical carrier and at least one polyoxometalate, with the proviso that the polyoxometalate is not H5PV2Mo10O40; K5Si(H2O)MnIIIW11O39; K4Si(H2O)MnIVW11O39; or K5CoIIIW12O40. The invention further relates to a method for removing a contaminant from an... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20080187602 - Stabilized lanthanum carbonate compositions: Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.... Agent: Darby & Darby P.C.

20080187603 - Article and method of novel antimicrobial delivery system: The present invention describes a novel antimicrobial ion delivery system (IDS) article, methods of making the article, and its applications in cleaning dentures and dentistry equipment. The novel IDS entails a source of oligodynamic metal ions embedded in a matrix that allows for the release of metal ions in water... Agent: Reyad Sawfta Quartek Corp.

20080187604 - Liquid chalcogenide compositions and methods of manufacturing and using the same: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.... Agent: Seed Intellectual Property Law Group PLLC

20080187605 - Preventing pathological nerve cell suicide (neuroapoptosis) in immature nervous systems: By disrupting a natural process used by developing mammalian brains to prune and delete surplus neurons, surgical anesthetics and other drugs that suppress brain activity in fetuses and infants can trigger permanent pathological brain damage. That type of damage can be prevented by drug interventions that block one or more... Agent: Patrick D. Kelly

20080187606 - Antiobesity composition: The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition. Also, the present invention provides an antiobesity composition comprising extract of Melissa and extract of Mori Folium as active ingredients, use of... Agent: Jhk Law

20080187607 - Systems, methods and apparatuses for epa exempt pesticidal compositions: The invention is directed to methods, apparatuses and EPA exempt compositions directed to producing a safe and effective chemical or biological barrier to protect human or animal subjects from insect and other nuisance pests.... Agent: Nixon & Vanderhye, PC

20080187608 - Enriched fractions from clary sage for the treatment of cancer, cardiovascular and inflammatory diseases: The present invention relates to the use of certain novel compositions from clary sage (Salvia sclarea) which are inhibitors of nuclear factor kappa B (NF-κB), oxidative stress (activation of Nerf2) and the activity of the endothelin receptor. In particular, it relates to useful enriched fractions and pharmaceutical compositions from clary... Agent: Passe' Intellectual Property, LLC

20080187609 - Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers: Methods and apparatus are provided to prevent, treat, and cure chemotherapy induced nausea in human beings. The inhalation of an effective amount of vaporized essential oil from Mentha piperita (peppermint oil) has been shown in practice to prevent, treat, and cure chemotherapy induced nausea. A simple hand-held apparatus provides the... Agent: William Banning Vail Iii

20080187610 - Extract of cercis chinensis having anti-oxidant activity and anti-aging activity, and cosmetical composition containing the extract for anti-oxidation, skin-aging protection and wrinkle improvement: The present invention relates to extract of Cercis chinensis having anti-oxidant activity and anti aging activity containing compound of chemical formula 1 to chemical formula 20, and cosmetical composition for anti-oxidation, skin-aging protection and wrinkle improvement containing the extract as effective ingredient. The extract of present invention having protective effect... Agent: Lucas & Mercanti, LLP

20080187611 - Type ii diabetes: The present invention features a formulation and method of administering the same to inhibit phosphodiesterase3 (PDE3) and increasing cAMP levels in beta cells, by providing a composition or treatment formulated with one or more processed Morinda citrifolia products, including TAHITIAN NONI® juice and juice concentrate, as derived from the Indian... Agent: Kirton & Mcconkie A Professional Corporation Attorneys At Law

20080187612 - Delivery systems: There is provided drug delivery systems for bioactive substances. In particular, there is provided a chocolate product containing bioactive compounds as well as desirable flavours and deliverability.... Agent: Reed Smith LLP